choline has been researched along with Fatty Liver, Nonalcoholic in 201 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "There is significant histologic and biochemical overlap between nonalcoholic fatty liver disease (NAFLD) and steatohepatitis associated with choline deficiency." | 9.16 | Choline intake in a large cohort of patients with nonalcoholic fatty liver disease. ( Colvin, RM; Diehl, A; Guerrerio, AL; Lavine, JE; Mohan, P; Molleston, JP; Murray, KF; Scheimann, AO; Schwartz, AK; Schwimmer, JB; Torbenson, MS, 2012) |
| "Humans eating low-choline diets develop fatty liver and liver damage." | 8.88 | Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression. ( Corbin, KD; Zeisel, SH, 2012) |
| " In a mouse NASH model with feeding of a methionine and choline-deficient (MCD) diet, MEL administration suppressed lipid accumulation and peroxidation, improved insulin sensitivity, and attenuated inflammation and fibrogenesis in the liver." | 8.31 | Melatonin alleviates diet-induced steatohepatitis by targeting multiple cell types in the liver to suppress inflammation and fibrosis. ( Ding, C; Ding, R; Dong, Z; Han, W; Jin, S; Li, D; Li, H; Ma, M; Song, M; Xu, L; Zhang, F; Zhang, O; Zhao, Y, 2023) |
| "The data reveals potential of saroglitazar for chemoprevention of hepatocellular carcinoma in patients with NAFLD/NASH." | 8.31 | Saroglitazar suppresses the hepatocellular carcinoma induced by intraperitoneal injection of diethylnitrosamine in C57BL/6 mice fed on choline deficient, l-amino acid- defined, high-fat diet. ( Bhoi, B; Giri, SR; Ingale, K; Jain, MR; Kadam, S; Nyska, A; Patel, H; Ranvir, R; Rath, A; Rathod, R; Sharma, A; Trivedi, C, 2023) |
| "Whether there is an association between dietary choline intake and non-alcoholic fatty liver disease (NAFLD) in American adults remains unclear." | 8.31 | Dietary choline intake and non-alcoholic fatty liver disease (NAFLD) in U.S. adults: National Health and Nutrition Examination Survey (NHANES) 2017-2018. ( Chai, C; Chen, L; Deng, MG; Liang, Y; Liu, F; Nie, JQ, 2023) |
| "Many studies suggest that trimethylamine-N-oxide (TMAO), a gut-flora-dependent metabolite of choline, contributes to the risk of cardiovascular diseases, but little is known for non-alcoholic fatty liver disease (NAFLD)." | 7.83 | Associations of gut-flora-dependent metabolite trimethylamine-N-oxide, betaine and choline with non-alcoholic fatty liver disease in adults. ( Chen, XL; Chen, YM; Ling, WH; Liu, Y; Tan, XY; Wang, C; Wang, LJ; Zhang, HW; Zheng, RD; Zhou, RF; Zhu, HL, 2016) |
| "We previously reported a model of non-alcoholic fatty liver disease (NAFLD) using spontaneously hypertensive rats (SHRs), fed a choline-deficient (CD) diet for 5 weeks, that hepatic steatosis but not fibrosis is developed through oxidative stress." | 7.83 | Enhancing hepatic fibrosis in spontaneously hypertensive rats fed a choline-deficient diet: a follow-up report on long-term effects of oxidative stress in non-alcoholic fatty liver disease. ( Arihiro, K; Ikuta, T; Kanno, K; Kishikawa, N; Sugiyama, A; Tazuma, S; Yamamoto, H, 2016) |
| "1% methionine in HFCD diet suppressed body weight gain, which was lower than that with control diet." | 7.83 | Evaluation of Methionine Content in a High-Fat and Choline-Deficient Diet on Body Weight Gain and the Development of Non-Alcoholic Steatohepatitis in Mice. ( Chiba, T; Itoh, T; Sato, Y; Suzuki, S; Umegaki, K, 2016) |
| "To investigate the influence of emodin on methionine-choline-deficient (MCD) diet-induced non-alcoholic fatty liver disease (NAFLD) in mice." | 7.81 | [Emodin worsens methionine-choline-deficient diet-induced non-alcoholic fatty liver disease in mice]. ( Liu, Q; Shi, M; Wang, F; Yu, F; Yu, N, 2015) |
| "Non-alcoholic fatty liver disease (NAFLD) embraces several forms of liver disorders involving fat disposition in hepatocytes ranging from simple steatosis to the severe stage, namely, non-alcoholic steatohepatitis (NASH)." | 6.82 | A Comparison of the Gene Expression Profiles of Non-Alcoholic Fatty Liver Disease between Animal Models of a High-Fat Diet and Methionine-Choline-Deficient Diet. ( Ahmeda, AF; Al Zarzour, RH; Alsalahi, A; Alshawsh, MA; Alshehade, SA; Mahmoud, AM; Saghir, SAM, 2022) |
| " In addition to free choline, phosphatidylcholine has been identified as a substrate for trimethylamine production by certain intestinal bacteria, thereby reducing host choline bioavailability and providing an additional link to the increased risk of cardiovascular disease faced by those with NAFLD." | 6.53 | Choline, Its Potential Role in Nonalcoholic Fatty Liver Disease, and the Case for Human and Bacterial Genes. ( Adams, LA; O'Sullivan, TA; Oddo, JL; Properzi, C; Sherriff, JL, 2016) |
| "Non-alcoholic fatty liver disease (NAFLD) is characterized by hepatic steatosis, inflammation, and fibrosis, as well as gut dysbiosis." | 5.91 | Gut microbiota and bile acids partially mediate the improvement of fibroblast growth factor 21 on methionine-choline-deficient diet-induced non-alcoholic fatty liver disease mice. ( Gong, F; Jia, S; Li, X; Lin, D; Liu, Z; Pan, J; Sun, Q; Wang, S; Zheng, M; Zhu, J, 2023) |
| "Nonalcoholic fatty liver disease (NAFLD) is a common liver disease highly associated with metabolic diseases and gut dysbiosis." | 5.91 | Fructooligosaccharides attenuate non-alcoholic fatty liver disease by remodeling gut microbiota and association with lipid metabolism. ( Chen, Q; Fan, Y; Gong, G; Huang, X; Huang, Y; Song, Y; Xi, S; Xu, H; Yan, C; Yang, R; Zhang, B, 2023) |
| "Non-alcoholic fatty liver disease (NAFLD) is the main cause of chronic liver disease, and its pathological development is closely related to the gut-liver axis." | 5.91 | Baicalein alleviates non-alcoholic fatty liver disease in mice by ameliorating intestinal barrier dysfunction. ( Chen, R; Dong, H; Fan, W; Guo, C; Guo, L; Li, Q; Qu, X; Wang, X; Zhang, X; Zhang, Y, 2023) |
| "Choline is a semi-essential nutrient involved in lipid and one-carbon metabolism that is compromised during MAFLD progression." | 5.91 | Prenatal Choline Supplement in a Maternal Obesity Model Modulates Offspring Hepatic Lipidomes. ( Bretter, R; Caviglia, JM; Jiang, X; Johnson, CH; Kadam, I; Korsmo, HW; Reaz, A; Saxena, A, 2023) |
| "Non-alcoholic fatty liver disease (NAFLD) includes a broad spectrum of liver diseases characterized by steatosis, inflammation, and fibrosis." | 5.72 | Hepatoprotective effects of gemigliptin and empagliflozin in a murine model of diet-induced non-alcoholic fatty liver disease. ( Choi, SE; Han, SJ; Heo, YJ; Jeon, JY; Kang, Y; Kim, DJ; Kim, HJ; Lee, KW; Lee, N, 2022) |
| "Auraptene (AUR) is a new FXR agonist with excellent safety and extensive pharmacological activities, while the lactone of AUR is vulnerable to esterolysis." | 5.72 | SU5, a new Auraptene analog with improved metabolic stability, ameliorates nonalcoholic fatty liver disease in methionine- and choline-deficient diet-fed db/db mice. ( Bian, D; Gan, J; Liu, R; Wang, C; Wen, F; Wu, X, 2022) |
| "Melatonin was administered at 20 mg/kg during the last 2 weeks." | 5.72 | Melatonin Attenuates Inflammation, Oxidative Stress, and DNA Damage in Mice with Nonalcoholic Steatohepatitis Induced by a Methionine- and Choline-Deficient Diet. ( Colares, JR; da Silva, JB; Hartmann, RM; Marroni, CA; Marroni, NP; Miguel, FM; Picada, JN; Schemitt, EG, 2022) |
| "Nonalcoholic fatty liver disease (NAFLD) is regarded as the most common liver disease with no approved therapeutic drug currently." | 5.62 | Silybin alleviates hepatic lipid accumulation in methionine-choline deficient diet-induced nonalcoholic fatty liver disease in mice via peroxisome proliferator-activated receptor α. ( Cheng, LH; Cui, S; Ge, CL; Guo, YT; Hao, HP; He, QX; Pan, XJ; Wang, GJ; Wang, H; Yan, TT; Zhang, PF; Zhou, JY, 2021) |
| "Inflammation drives the pathogenesis of nonalcoholic steatohepatitis (NASH)." | 5.62 | Methionine- and Choline-Deficient Diet-Induced Nonalcoholic Steatohepatitis Is Associated with Increased Intestinal Inflammation. ( Alpini, G; Francis, H; Glaser, S; Li, H; Li, Q; Matthews, DR; Wu, C; Zhou, J, 2021) |
| "PTHrP may aggravate MCD-induced NAFLD in mice by promoting the deposition of lipid droplets in the hepatocytes." | 5.62 | [Parathyroid hormone-related protein aggravates nonalcoholic fatty liver disease induced by methionine choline-deficient diet in mice]. ( Bai, L; Diao, N; Qin, B, 2021) |
| "The pathogenesis of nonalcoholic fatty liver disease (NAFLD) has not be fully elucidated, and the lack of therapeutic strategies for NAFLD is an urgent health problem." | 5.56 | Downregulation of GNAI3 Promotes the Pathogenesis of Methionine/Choline-Deficient Diet-Induced Nonalcoholic Fatty Liver Disease. ( Ge, K; Jia, C; Lu, J; Zhu, H, 2020) |
| "Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide, ranging from steatosis to non-alcoholic steatohepatitis (NASH)." | 5.51 | Cerium oxide nanoparticles display antilipogenic effect in rats with non-alcoholic fatty liver disease. ( Carvajal, S; Casals, E; Casals, G; Fernández-Varo, G; González de la Presa, B; Jiménez, W; Morales-Ruíz, M; Oró, D; Parra, M; Pastor, Ó; Perramón, M; Puntes, V; Ribera, J, 2019) |
| "Non-alcoholic fatty liver disease (NAFLD) is associated with low-grade chronic inflammation and intestinal dysbiosis." | 5.51 | Sinapine reduces non-alcoholic fatty liver disease in mice by modulating the composition of the gut microbiota. ( Li, J; Li, Y; Liu, Y; Su, Q, 2019) |
| " While the rich bioavailability research of curcumin, BDMC is the poor studies." | 5.43 | Hepatoprotective Effect and Synergism of Bisdemethoycurcumin against MCD Diet-Induced Nonalcoholic Fatty Liver Disease in Mice. ( Ahn, YS; Cha, SW; Han, SH; Kang, OH; Kim, SB; Kong, R; Kwon, DY; Lee, YS; Seo, YS, 2016) |
| "Nonalcoholic fatty liver disease (NAFLD) refers to hepatic pathologies, including simple fatty liver (SFL), nonalcoholic steatohepatitis (NASH), fibrosis, and cirrhosis, that may progress to hepatocellular carcinoma." | 5.43 | Effects of Nonalcoholic Fatty Liver Disease on Hepatic CYP2B1 and in Vivo Bupropion Disposition in Rats Fed a High-Fat or Methionine/Choline-Deficient Diet. ( Cho, HJ; Cho, SJ; Chong, S; Chung, SJ; Kang, IM; Kim, DD; Kim, SB; Lee, JI; Yoon, IS, 2016) |
| "Quercetin (50 mg/kg) was given by oral route daily." | 5.38 | Quercetin treatment ameliorates inflammation and fibrosis in mice with nonalcoholic steatohepatitis. ( González-Gallego, J; Marcolin, E; Marroni, N; San-Miguel, B; Tieppo, J; Tuñón, MJ; Vallejo, D, 2012) |
| "A mixture of natural ingredients, namely, DHA, phosphatidylcholine, silymarin, choline, curcumin and d-α-tocopherol, was studied in subjects with non-alcoholic fatty liver disease (NAFLD)." | 5.34 | Randomised trial of chronic supplementation with a nutraceutical mixture in subjects with non-alcoholic fatty liver disease. ( Ammollo, CT; Barone, M; Cerletti, C; Colucci, M; Costanzo, S; De Bartolomeo, G; de Gaetano, G; Di Castelnuovo, A; Iacoviello, L; Incampo, F; Portincasa, P; Semeraro, F; Semeraro, N; Storto, M, 2020) |
| "There is significant histologic and biochemical overlap between nonalcoholic fatty liver disease (NAFLD) and steatohepatitis associated with choline deficiency." | 5.16 | Choline intake in a large cohort of patients with nonalcoholic fatty liver disease. ( Colvin, RM; Diehl, A; Guerrerio, AL; Lavine, JE; Mohan, P; Molleston, JP; Murray, KF; Scheimann, AO; Schwartz, AK; Schwimmer, JB; Torbenson, MS, 2012) |
| "The available literature has proposed mechanisms for an association between gut microbiota and NASH, such as: modification energy homeostasis, lipopolysaccharides (LPS)-endotoxemia, increased endogenous production of ethanol, and alteration in the metabolism of bile acid and choline." | 4.98 | Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis. ( Cesar, DE; de Castro Ferreira, LEVV; de Faria Ghetti, F; de Oliveira, JM; Moreira, APB; Oliveira, DG, 2018) |
| " The mechanisms underlying gut microbiota-mediated development of NAFLD include modulation of host energy metabolism, insulin sensitivity, and bile acid and choline metabolism." | 4.98 | Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota. ( Han, R; Li, H; Ma, J, 2018) |
| "Humans eating low-choline diets develop fatty liver and liver damage." | 4.88 | Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression. ( Corbin, KD; Zeisel, SH, 2012) |
| " In a mouse NASH model with feeding of a methionine and choline-deficient (MCD) diet, MEL administration suppressed lipid accumulation and peroxidation, improved insulin sensitivity, and attenuated inflammation and fibrogenesis in the liver." | 4.31 | Melatonin alleviates diet-induced steatohepatitis by targeting multiple cell types in the liver to suppress inflammation and fibrosis. ( Ding, C; Ding, R; Dong, Z; Han, W; Jin, S; Li, D; Li, H; Ma, M; Song, M; Xu, L; Zhang, F; Zhang, O; Zhao, Y, 2023) |
| "The data reveals potential of saroglitazar for chemoprevention of hepatocellular carcinoma in patients with NAFLD/NASH." | 4.31 | Saroglitazar suppresses the hepatocellular carcinoma induced by intraperitoneal injection of diethylnitrosamine in C57BL/6 mice fed on choline deficient, l-amino acid- defined, high-fat diet. ( Bhoi, B; Giri, SR; Ingale, K; Jain, MR; Kadam, S; Nyska, A; Patel, H; Ranvir, R; Rath, A; Rathod, R; Sharma, A; Trivedi, C, 2023) |
| "Here, we examine the impact of housing temperature on steatosis, hepatocellular damage, hepatic inflammation, and fibrosis in NASH diet, methionine and choline deficient diet, and western diet + carbon tetrachloride experimental models of NAFLD in C57BL/6 mice." | 4.31 | Thermoneutral housing shapes hepatic inflammation and damage in mouse models of non-alcoholic fatty liver disease. ( Alarcon, PC; Damen, MSMA; Divanovic, S; Giles, DA; Moreno-Fernandez, ME; Oates, JR; Sawada, K; Stankiewicz, TE; Szabo, S, 2023) |
| " Previously, we reported a dietary mouse NASH model with a choline-deficient, methionine-lowered, L-amino-acid-defined, high-fat diet containing shortening without trans fatty acids (CDAA-HF-T[-]), which rapidly induces fibrosis and proliferative lesions in the liver." | 4.31 | Nonalcoholic steatohepatitis-associated hepatocarcinogenesis in mice fed a modified choline-deficient, methionine-lowered, L-amino acid-defined diet and the role of signal changes. ( Abe, A; Miyajima, K; Nakae, D; Nakane, S; Suzuki-Kemuriyama, N; Yuki, M, 2023) |
| "Whether there is an association between dietary choline intake and non-alcoholic fatty liver disease (NAFLD) in American adults remains unclear." | 4.31 | Dietary choline intake and non-alcoholic fatty liver disease (NAFLD) in U.S. adults: National Health and Nutrition Examination Survey (NHANES) 2017-2018. ( Chai, C; Chen, L; Deng, MG; Liang, Y; Liu, F; Nie, JQ, 2023) |
| " Both acute and chronic liver injury models were used: lipopolysaccharide/adenosine-triphosphate to induce in vivo NLRP3 activation, choline-deficient, L-amino acid-defined high-fat diet, and Western-type diet to induce fibrotic nonalcoholic steatohepatitis (NASH)." | 4.12 | Cell-specific Deletion of NLRP3 Inflammasome Identifies Myeloid Cells as Key Drivers of Liver Inflammation and Fibrosis in Murine Steatohepatitis. ( Booshehri, LM; Broderick, L; Feldstein, AE; Friess, H; Hartmann, D; Hoffman, HM; Kaufmann, B; Kim, AD; Kui, L; Leszczynska, A; Reca, A; Wree, A, 2022) |
| "Trimethylamine N-oxide (TMAO), choline and betaine serum levels have been associated with metabolic diseases including type 2 diabetes (T2D) and non-alcoholic fatty liver disease (NAFLD)." | 4.02 | Trimethylamine N-oxide levels are associated with NASH in obese subjects with type 2 diabetes. ( Aguilar-Salinas, C; Campos-Pérez, F; Canizales-Quinteros, S; Gómez-Pérez, F; González-González, I; Grandini-Rosales, P; Hazen, SL; Hernández-Pando, R; Huertas-Vazquez, A; Hui, ST; Larrieta-Carrasco, E; León-Mimila, P; Li, XS; López-Contreras, B; Lusis, AJ; Macías-Kauffer, L; Morán-Ramos, S; Ocampo-Medina, E; Olivares-Arevalo, M; Shih, DM; Villamil-Ramírez, H; Villarreal-Molina, T; Wang, Z, 2021) |
| " To induce liver steatosis and inflammation, we fed C57/black female mice (8 weeks old) a methionine-choline deficient diet (MCD diet) for 6 weeks." | 3.96 | Automated thermal imaging for the detection of fatty liver disease. ( Balint-Lahat, N; Ben-Ari, Z; Brzezinski, RY; Finchelman, JM; Grossman, E; Hoffer, O; Leor, J; Levin-Kotler, L; Lewis, N; Naftali-Shani, N; Ovadia-Blechman, Z; Rabin, N; Safran, M; Sternfeld, A; Tepper-Shaihov, O; Unis, R; Zimmer, Y, 2020) |
| "Many studies suggest that trimethylamine-N-oxide (TMAO), a gut-flora-dependent metabolite of choline, contributes to the risk of cardiovascular diseases, but little is known for non-alcoholic fatty liver disease (NAFLD)." | 3.83 | Associations of gut-flora-dependent metabolite trimethylamine-N-oxide, betaine and choline with non-alcoholic fatty liver disease in adults. ( Chen, XL; Chen, YM; Ling, WH; Liu, Y; Tan, XY; Wang, C; Wang, LJ; Zhang, HW; Zheng, RD; Zhou, RF; Zhu, HL, 2016) |
| "We previously reported a model of non-alcoholic fatty liver disease (NAFLD) using spontaneously hypertensive rats (SHRs), fed a choline-deficient (CD) diet for 5 weeks, that hepatic steatosis but not fibrosis is developed through oxidative stress." | 3.83 | Enhancing hepatic fibrosis in spontaneously hypertensive rats fed a choline-deficient diet: a follow-up report on long-term effects of oxidative stress in non-alcoholic fatty liver disease. ( Arihiro, K; Ikuta, T; Kanno, K; Kishikawa, N; Sugiyama, A; Tazuma, S; Yamamoto, H, 2016) |
| "1% methionine in HFCD diet suppressed body weight gain, which was lower than that with control diet." | 3.83 | Evaluation of Methionine Content in a High-Fat and Choline-Deficient Diet on Body Weight Gain and the Development of Non-Alcoholic Steatohepatitis in Mice. ( Chiba, T; Itoh, T; Sato, Y; Suzuki, S; Umegaki, K, 2016) |
| "To investigate the influence of emodin on methionine-choline-deficient (MCD) diet-induced non-alcoholic fatty liver disease (NAFLD) in mice." | 3.81 | [Emodin worsens methionine-choline-deficient diet-induced non-alcoholic fatty liver disease in mice]. ( Liu, Q; Shi, M; Wang, F; Yu, F; Yu, N, 2015) |
| "Methionine-choline deficient (MCD) diet duration necessary for development of non-alcoholic fatty liver disease (NAFLD) and the dynamic of lipid profile and fatty acids are not completely established." | 3.80 | Time-dependent changes and association between liver free fatty acids, serum lipid profile and histological features in mice model of nonalcoholic fatty liver disease. ( Aleksić, V; Duričić, I; Ješić-Vukićević, R; Jorgačević, B; Mladenović, DR; Radosavljević, TS; Šobajić, SS; Stanković, MN; Timić, J; Vučević, DB, 2014) |
| "Choline deficiency has been shown to induce liver fat accumulation in both rodent and human studies." | 3.80 | Higher dietary choline intake is associated with lower risk of nonalcoholic fatty liver in normal-weight Chinese women. ( Gao, YT; Li, H; Shu, XO; Xiang, YB; Yang, G; Yu, D; Zhang, X; Zheng, W, 2014) |
| "Nonalcoholic fatty liver disease (NAFLD) is a prevalent condition among postmenopausal women that can lead to severe liver dysfunction and increased mortality." | 3.01 | The Role of Choline, Soy Isoflavones, and Probiotics as Adjuvant Treatments in the Prevention and Management of NAFLD in Postmenopausal Women. ( DiStefano, JK, 2023) |
| "Non-alcoholic fatty liver disease (NAFLD) embraces several forms of liver disorders involving fat disposition in hepatocytes ranging from simple steatosis to the severe stage, namely, non-alcoholic steatohepatitis (NASH)." | 2.82 | A Comparison of the Gene Expression Profiles of Non-Alcoholic Fatty Liver Disease between Animal Models of a High-Fat Diet and Methionine-Choline-Deficient Diet. ( Ahmeda, AF; Al Zarzour, RH; Alsalahi, A; Alshawsh, MA; Alshehade, SA; Mahmoud, AM; Saghir, SAM, 2022) |
| "Nonalcoholic fatty liver disease (NAFLD) is the liver manifestation of metabolic syndrome and is the most common chronic liver disease in the world." | 2.82 | The contribution of the gut-liver axis to the immune signaling pathway of NAFLD. ( Cai, J; Li, H; Liu, J; She, ZG; Wu, A, 2022) |
| "The prevalence of nonalcoholic fatty liver disease (NAFLD) is increasing worldwide." | 2.66 | One-Carbon Metabolism and Nonalcoholic Fatty Liver Disease: The Crosstalk between Nutrients, Microbiota, and Genetics. ( Chmurzynska, A; Martínez, JA; Milagro, FI; Muzsik, A; Radziejewska, A, 2020) |
| "Choline is a water-soluble nutrient essential for human life." | 2.66 | The Relationship between Choline Bioavailability from Diet, Intestinal Microbiota Composition, and Its Modulation of Human Diseases. ( Allison, J; Arboleya, S; Arias, JL; Arias, N; Gueimonde, M; Higarza, SG; Kaliszewska, A, 2020) |
| "Nonalcoholic fatty liver disease (NAFLD) is the most common liver disorder in the world, yet the pathogenesis of the disease is not well elucidated." | 2.55 | Nonalcoholic Fatty Liver Disease, the Gut Microbiome, and Diet. ( Gibson, DL; Hekmatdoost, A; Mokhtari, Z, 2017) |
| " In addition to free choline, phosphatidylcholine has been identified as a substrate for trimethylamine production by certain intestinal bacteria, thereby reducing host choline bioavailability and providing an additional link to the increased risk of cardiovascular disease faced by those with NAFLD." | 2.53 | Choline, Its Potential Role in Nonalcoholic Fatty Liver Disease, and the Case for Human and Bacterial Genes. ( Adams, LA; O'Sullivan, TA; Oddo, JL; Properzi, C; Sherriff, JL, 2016) |
| "Gata4 expression is repressed during NAFLD progression, however how it functions in this situation remains unclear." | 1.91 | Deleting Gata4 in hepatocytes promoted the progression of NAFLD via increasing steatosis and apoptosis, and desensitizing insulin signaling. ( Bily, D; Cheng, H; Ding, Z; He, L; Liu, L; Wang, X; Wu, C; Xie, L; Zhang, K, 2023) |
| "Non-alcoholic fatty liver disease (NAFLD) is characterized by hepatic steatosis, inflammation, and fibrosis, as well as gut dysbiosis." | 1.91 | Gut microbiota and bile acids partially mediate the improvement of fibroblast growth factor 21 on methionine-choline-deficient diet-induced non-alcoholic fatty liver disease mice. ( Gong, F; Jia, S; Li, X; Lin, D; Liu, Z; Pan, J; Sun, Q; Wang, S; Zheng, M; Zhu, J, 2023) |
| "Non-alcoholic fatty liver disease (NAFLD) comprises a spectrum of liver damage directly related to diabetes, obesity, and metabolic syndrome." | 1.91 | (Pro)Renin Receptor Antagonism Attenuates High-Fat-Diet-Induced Hepatic Steatosis. ( Cooper, SG; Feng Earley, Y; Gayban, AJB; Kleemann, R; Regalado, E; Souza, LAC, 2023) |
| "Nonalcoholic fatty liver disease (NAFLD) is a common liver disease highly associated with metabolic diseases and gut dysbiosis." | 1.91 | Fructooligosaccharides attenuate non-alcoholic fatty liver disease by remodeling gut microbiota and association with lipid metabolism. ( Chen, Q; Fan, Y; Gong, G; Huang, X; Huang, Y; Song, Y; Xi, S; Xu, H; Yan, C; Yang, R; Zhang, B, 2023) |
| "Non-alcoholic fatty liver disease (NAFLD) is the main cause of chronic liver disease, and its pathological development is closely related to the gut-liver axis." | 1.91 | Baicalein alleviates non-alcoholic fatty liver disease in mice by ameliorating intestinal barrier dysfunction. ( Chen, R; Dong, H; Fan, W; Guo, C; Guo, L; Li, Q; Qu, X; Wang, X; Zhang, X; Zhang, Y, 2023) |
| "Choline is a semi-essential nutrient involved in lipid and one-carbon metabolism that is compromised during MAFLD progression." | 1.91 | Prenatal Choline Supplement in a Maternal Obesity Model Modulates Offspring Hepatic Lipidomes. ( Bretter, R; Caviglia, JM; Jiang, X; Johnson, CH; Kadam, I; Korsmo, HW; Reaz, A; Saxena, A, 2023) |
| "Chrysin (CH) has been reported to have anti-inflammatory effects but shows lower bioavailability." | 1.91 | Chrysin and its nanoliposome ameliorated non-alcoholic steatohepatitis via inhibiting TLR4 signalling pathway. ( Gong, X; Hu, J; Jiang, N; Kuang, G; Liu, H; Liu, J; Wan, J; Wu, S; Yin, X, 2023) |
| "Nonalcoholic fatty liver disease (NAFLD) is one of the etiologies that contribute to hepatocellular carcinoma (HCC), and chronic inflammation is one of the proposed mediators of HCC." | 1.91 | Absence of Either Ripk3 or Mlkl Reduces Incidence of Hepatocellular Carcinoma Independent of Liver Fibrosis. ( Deepa, SS; Freeman, WM; Georgescu, C; Haritha, NH; Janknecht, R; Luo, W; Miller, BF; Mohammed, S; Nicklas, EH; Oh, S; Ohene-Marfo, P; Thadathil, N; Tran, AL; Van Der Veldt, M; Wang, D; Wren, JD, 2023) |
| "Individuals with nonalcoholic fatty liver disease (NAFLD) have an altered gut microbiota composition." | 1.91 | Faecal Microbiota transplantation affects liver DNA methylation in Non-alcoholic fatty liver disease: a multi-omics approach. ( Bruinstroop, E; Henneman, P; Holleboom, AG; Levin, E; Madsen, MS; Mak, AL; Meijnikman, AS; Mol, F; Nieuwdorp, M; Scheithauer, TPM; Smits, L; Stols-Gonçalves, D; van der Vossen, EWJ; Verheij, J; Witjes, J, 2023) |
| "However, the effect of ACT001 on nonalcoholic steatohepatitis (NASH) is unknown." | 1.91 | iTRAQ-based quantitative proteomics analysis of the effect of ACT001 on non-alcoholic steatohepatitis in mice. ( Chen, Z; Chu, W; Li, P; Liu, Y; Mi, Y; Niu, B; Wu, X; Zhou, H; Zhou, Y, 2023) |
| "However, its impact on nonalcoholic steatohepatitis (NASH) development remains unclear." | 1.91 | Icariin Supplementation Suppresses the Markers of Ferroptosis and Attenuates the Progression of Nonalcoholic Steatohepatitis in Mice Fed a Methionine Choline-Deficient Diet. ( Choi, H; Choi, J; Chung, J, 2023) |
| "plantarum against nonalcoholic steatohepatitis (NASH) and its underlying mechanisms remain unelucidated." | 1.91 | Lactobacillus plantarum ameliorates NASH-related inflammation by upregulating L-arginine production. ( Gee, HY; Kim, DY; Park, JY, 2023) |
| "Non-alcoholic fatty liver disease (NAFLD) includes a broad spectrum of liver diseases characterized by steatosis, inflammation, and fibrosis." | 1.72 | Hepatoprotective effects of gemigliptin and empagliflozin in a murine model of diet-induced non-alcoholic fatty liver disease. ( Choi, SE; Han, SJ; Heo, YJ; Jeon, JY; Kang, Y; Kim, DJ; Kim, HJ; Lee, KW; Lee, N, 2022) |
| "Auraptene (AUR) is a new FXR agonist with excellent safety and extensive pharmacological activities, while the lactone of AUR is vulnerable to esterolysis." | 1.72 | SU5, a new Auraptene analog with improved metabolic stability, ameliorates nonalcoholic fatty liver disease in methionine- and choline-deficient diet-fed db/db mice. ( Bian, D; Gan, J; Liu, R; Wang, C; Wen, F; Wu, X, 2022) |
| "Non-alcoholic fatty liver disease (NAFLD) is currently a growing epidemic disease that can lead to cirrhosis and hepatic cancer when it evolves into non-alcoholic steatohepatitis (NASH), a gap not well understood." | 1.72 | Hepatic galectin-3 is associated with lipid droplet area in non-alcoholic steatohepatitis in a new swine model. ( Alastrué-Vera, V; Arnal, C; Barranquero, C; García-Gil, A; Gascón, S; Gonzalo-Romeo, G; Güemes, A; Gutiérrez-Blázquez, D; Herrera-Marcos, LV; Herrero-Continente, T; Lou-Bonafonte, JM; Macías-Herranz, M; Martínez-Beamonte, R; Osada, J; Puente-Lanzarote, JJ; Rodríguez-Yoldi, MJ; Surra, JC, 2022) |
| "Autophagy affects NAFLD by improving steatosis." | 1.72 | Ubiquitin-specific peptidase 10 ameliorates hepatic steatosis in nonalcoholic steatohepatitis model by restoring autophagic activity. ( Xin, SL; Yu, YY, 2022) |
| "Melatonin was administered at 20 mg/kg during the last 2 weeks." | 1.72 | Melatonin Attenuates Inflammation, Oxidative Stress, and DNA Damage in Mice with Nonalcoholic Steatohepatitis Induced by a Methionine- and Choline-Deficient Diet. ( Colares, JR; da Silva, JB; Hartmann, RM; Marroni, CA; Marroni, NP; Miguel, FM; Picada, JN; Schemitt, EG, 2022) |
| "Chlorogenic acid (CGA) is a natural polyphenolic compound." | 1.72 | Chlorogenic acid alleviated liver fibrosis in methionine and choline deficient diet-induced nonalcoholic steatohepatitis in mice and its mechanism. ( Guo, Q; Ji, L; Kai, G; Lu, B; Miao, H; Ouyang, H; Wei, M, 2022) |
| "During NAFLD progression from steatosis to steatohepatitis, MCD rats exhibit an increase in Zn and a decrease in Fe levels both in serum and tissue associated with alterations in hepatic MMPs and their inhibitors, and fatty acids." | 1.72 | MCD Diet Rat Model Induces Alterations in Zinc and Iron during NAFLD Progression from Steatosis to Steatohepatitis. ( Cagna, M; Croce, AC; Di Pasqua, LG; Ferrigno, A; Mannucci, B; Palladini, G; Perlini, S; Profumo, A; Vairetti, M, 2022) |
| "Non-alcoholic fatty liver disease (NAFLD), one of the most common forms of chronic liver disease, is characterized by the excessive accumulation of lipid species in hepatocytes." | 1.72 | Lipidomic profiling of the hepatic esterified fatty acid composition in diet-induced nonalcoholic fatty liver disease in genetically diverse Collaborative Cross mice. ( Avigan, MI; Beland, FA; da Costa, GG; de Conti, A; Nagumalli, SK; Pogribny, IP; Rusyn, I; Tryndyak, VP; Willett, RA, 2022) |
| "The prevalence of nonalcoholic fatty liver disease (NAFLD) has reached epidemic proportions globally as a result of the rapid increase in obesity." | 1.72 | Hepatocyte-Secreted Autotaxin Exacerbates Nonalcoholic Fatty Liver Disease Through Autocrine Inhibition of the PPARα/FGF21 Axis. ( Cheong, LY; Cheung, BMY; Hoo, RLC; Hu, Y; Ku, KC; Li, T; Qiu, H; Song, E; Wang, C; Wang, Q; Wang, Y; Wu, X; Xu, A, 2022) |
| "Non-alcoholic fatty liver disease (NAFLD) ranks first among liver diseases in Western countries." | 1.72 | Differential progression of unhealthy diet-induced hepatocellular carcinoma in obese and non-obese mice. ( Farazi, PA; Fisher, KW; Hymel, E; Vlock, E, 2022) |
| "Non-alcoholic fatty liver disease (NAFLD), represents an unmet medical need that can progress to non-alcoholic steatohepatitis (NASH), which, without intervention, can result in the development of cirrhosis and hepatocellular carcinoma (HCC)." | 1.72 | IL-23 signaling is not an important driver of liver inflammation and fibrosis in murine non-alcoholic steatohepatitis models. ( Brightbill, HD; Ding, N; Flanagan, S; Ghilardi, N; Heredia, JE; Jones, C; Leong, L; Martinez, AP; Martzall, A; Nunez, V; Scherl, A; Sorenson, C, 2022) |
| "Gut microbiota dysbiosis is associated with the development of non-alcoholic steatohepatitis (NASH) through modulation of gut barrier, inflammation, lipid metabolism, bile acid signaling and short-chain fatty acid production." | 1.72 | Marked gut microbiota dysbiosis and increased imidazole propionate are associated with a NASH Göttingen Minipig model. ( Ahmad, HFB; Christoffersen, BØ; Cirera, S; Geng, D; Hansen, AK; Hyötyläinen, T; Jakobsen, RR; Kot, W; Lützhøft, DO; Nielsen, DS; Pedersen, HD; Pedersen, KM; Sinioja, T; Straarup, EM, 2022) |
| "Nonalcoholic fatty liver disease affects about 24% of the world's population and may progress to nonalcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma (HCC)." | 1.72 | Differential methylation patterns in lean and obese non-alcoholic steatohepatitis-associated hepatocellular carcinoma. ( Farazi, PA; Fisher, KW; Hymel, E, 2022) |
| "Rosmarinic acid (RA) has positive effects on the liver injuries; nevertheless, its mechanisms are not completely studied." | 1.72 | SIRT1/NFκB pathway mediates anti-inflammatory and anti-apoptotic effects of rosmarinic acid on in a mouse model of nonalcoholic steatohepatitis (NASH). ( Bassirian, M; Changizi, Z; Komeili-Movahhed, T; Moslehi, A, 2022) |
| "Liraglutide treatment did not prevent lipid deposition in the liver of MCD-fed mice but limited the accumulation of C16 and C24-ceramide/sphingomyelin species." | 1.62 | The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet. ( Bochaton-Piallat, ML; De Vito, C; Dibner, C; Gaïa, N; Jornayvaz, FR; Lazarevic, V; Loizides-Mangold, U; Montandon, SA; Perroud, E; Schrenzel, J; Somm, E, 2021) |
| "Nonalcoholic fatty liver disease (NAFLD) is regarded as the most common liver disease with no approved therapeutic drug currently." | 1.62 | Silybin alleviates hepatic lipid accumulation in methionine-choline deficient diet-induced nonalcoholic fatty liver disease in mice via peroxisome proliferator-activated receptor α. ( Cheng, LH; Cui, S; Ge, CL; Guo, YT; Hao, HP; He, QX; Pan, XJ; Wang, GJ; Wang, H; Yan, TT; Zhang, PF; Zhou, JY, 2021) |
| "Inflammation drives the pathogenesis of nonalcoholic steatohepatitis (NASH)." | 1.62 | Methionine- and Choline-Deficient Diet-Induced Nonalcoholic Steatohepatitis Is Associated with Increased Intestinal Inflammation. ( Alpini, G; Francis, H; Glaser, S; Li, H; Li, Q; Matthews, DR; Wu, C; Zhou, J, 2021) |
| "PTHrP may aggravate MCD-induced NAFLD in mice by promoting the deposition of lipid droplets in the hepatocytes." | 1.62 | [Parathyroid hormone-related protein aggravates nonalcoholic fatty liver disease induced by methionine choline-deficient diet in mice]. ( Bai, L; Diao, N; Qin, B, 2021) |
| "The pathogenesis of nonalcoholic fatty liver disease (NAFLD) has not be fully elucidated, and the lack of therapeutic strategies for NAFLD is an urgent health problem." | 1.56 | Downregulation of GNAI3 Promotes the Pathogenesis of Methionine/Choline-Deficient Diet-Induced Nonalcoholic Fatty Liver Disease. ( Ge, K; Jia, C; Lu, J; Zhu, H, 2020) |
| "A proportion of NAFLD patients develop hepatic inflammation, known as Non-Alcoholic Steatohepatitis (NASH), which can end up in cirrhosis, or Hepatocellular Carcinoma (HCC)." | 1.56 | Metabolic impact of partial hepatectomy in the non-alcoholic steatohepatitis animal model of methionine-choline deficient diet. ( Angulo, S; Carril, E; Godzien, J; Lanzón, B; Rupérez, FJ; Valdecantos, MP; Valverde, ÁM, 2020) |
| "Non-alcoholic fatty liver disease (NAFLD) or non-alcoholic seatohepatitis (NASH) is one of the major health problems world wide, because of increased abdominal obesity." | 1.56 | Reduced Serum Cholesterol and Triglyceride Levels in a Choline-Deficient L-Amino Acid-Defined High-Fat Diet (CDAHFD)-Induced Mouse Model of Non-alcoholic Steatohepatitis (NASH). ( Hiraoka, Y; Kume, N; Shimizu, R; Torii, H; Yasuda, D, 2020) |
| "In cynomolgus monkeys with nonalcoholic fatty liver disease (NAFLD), administration of B1344 via subcutaneous injection for 11 weeks caused a profound reduction of hepatic steatosis, inflammation, and fibrosis, along with amelioration of liver injury and hepatocyte death, as evidenced by liver biopsy specimen and biochemical analysis." | 1.56 | The Effects of B1344, a Novel Fibroblast Growth Factor 21 Analog, on Nonalcoholic Steatohepatitis in Nonhuman Primates. ( Chen, J; Cui, A; Gao, J; Han, J; Ji, S; Li, J; Li, Y; Liu, Z; Ma, F; Ma, X; Tai, P; Wang, G; Wang, T; Xue, Y, 2020) |
| "In non-alcoholic steatohepatitis (NASH), many lines of investigation have reported a dysregulation in lipid homeostasis, leading to intrahepatic lipid accumulation." | 1.56 | Exogenous Liposomal Ceramide-C6 Ameliorates Lipidomic Profile, Energy Homeostasis, and Anti-Oxidant Systems in NASH. ( Andreola, F; Argemi, J; Bataller, R; Caballeria, J; Cowart, LA; De Chiara, F; Fondevila, C; Fox, T; Frenguelli, L; Kester, M; Levi, A; Longato, L; Luong, TV; Massey, V; Mazza, G; Montefusco, D; Omenetti, S; Pinzani, M; Rombouts, K; Shanmugavelandy, SS; Zanieri, F, 2020) |
| "Nonalcoholic fatty liver disease (NAFLD) represents a hepatic manifestation of metabolic syndrome." | 1.56 | Effect of Betaine Supplementation on Liver Tissue and Ultrastructural Changes in Methionine-Choline-Deficient Diet-Induced NAFLD. ( Jadžić, J; Jorgačević, B; Labudović-Borović, M; Mladenović, D; Radosavljević, T; Vesković, M; Vučević, D; Vukićević, D, 2020) |
| "Nonalcoholic steatohepatitis (NASH) is a form of liver disease characterized by steatosis, necroinflammation, and fibrosis, resulting in cirrhosis and cancer." | 1.56 | A trans fatty acid substitute enhanced development of liver proliferative lesions induced in mice by feeding a choline-deficient, methionine-lowered, L-amino acid-defined, high-fat diet. ( Abe, A; Miyajima, K; Nakae, D; Ogawa, S; Sano, R; Suzuki-Kemuriyama, N; Uno, K; Watanabe, A; Yuki, M, 2020) |
| "Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide, ranging from steatosis to non-alcoholic steatohepatitis (NASH)." | 1.51 | Cerium oxide nanoparticles display antilipogenic effect in rats with non-alcoholic fatty liver disease. ( Carvajal, S; Casals, E; Casals, G; Fernández-Varo, G; González de la Presa, B; Jiménez, W; Morales-Ruíz, M; Oró, D; Parra, M; Pastor, Ó; Perramón, M; Puntes, V; Ribera, J, 2019) |
| "For this purpose, we established a NAFLD model by feeding C57BL/6J mice a methionine‑choline‑deficient diet." | 1.51 | Role and mechanisms of action of microRNA‑21 as regards the regulation of the WNT/β‑catenin signaling pathway in the pathogenesis of non‑alcoholic fatty liver disease. ( Chen, X; Huang, YM; Li, CP; Lü, MH; Shi, L; Wang, XM; Wang, XY, 2019) |
| "Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in western countries, with a continuously rising incidence." | 1.51 | Intestinal Microbiota Protects against MCD Diet-Induced Steatohepatitis. ( Bennek, E; Candels, LS; Elfers, C; Gassler, N; Heymann, F; Kilic, K; Mohs, A; Penders, J; Schneider, KM; Schneider, LB; Trautwein, C, 2019) |
| "Rats were fed with high fat diet and NAFLD rats were orally treated with different doses of betaine or choline or folic acid for 28 days." | 1.51 | Evaluating the therapeutic potential of one-carbon donors in nonalcoholic fatty liver disease. ( Ali, MA; Bakir, MB; Kamel, MA; Khalifa, EA; Refaat, R; Salama, MA, 2019) |
| "Non-alcoholic fatty liver disease (NAFLD) is associated with low-grade chronic inflammation and intestinal dysbiosis." | 1.51 | Sinapine reduces non-alcoholic fatty liver disease in mice by modulating the composition of the gut microbiota. ( Li, J; Li, Y; Liu, Y; Su, Q, 2019) |
| "Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in Western countries." | 1.48 | Dual role of protein tyrosine phosphatase 1B in the progression and reversion of non-alcoholic steatohepatitis. ( Addante, A; Barahona, I; García-Monzón, C; González-Rodríguez, Á; Laiglesia, LM; Moreno-Aliaga, MJ; Pardo, V; Rada, P; Rey, E; Ruiz, L; Sánchez, A; Valdecantos, MP; Valverde, ÁM, 2018) |
| "emblica (WEPE) on nonalcoholic steatohepatitis (NASH) was evaluated." | 1.48 | Effect of Phyllanthus emblica L. fruit on methionine and choline-deficiency diet-induced nonalcoholic steatohepatitis. ( Huang, CZ; Lin, JH; Tung, YT; Yen, GC, 2018) |
| "Non-alcoholic fatty liver disease (NAFLD) is an important co-morbidity associated with obesity and a precursor to steatohepatitis." | 1.46 | Enhanced offspring predisposition to steatohepatitis with maternal high-fat diet is associated with epigenetic and microbiome alterations. ( Alfaro, M; Chintapalli, SV; Kang, P; Shankar, K; Thakali, KM; Wankhade, UD; Zhong, Y, 2017) |
| "Non-alcoholic fatty liver disease (NAFLD) is the most common form of liver disease and ranges from isolated steatosis to NASH." | 1.46 | Fatty acids in non-alcoholic steatohepatitis: Focus on pentadecanoic acid. ( Beretta, L; Fallon, M; Gjuka, D; Harrison, SA; Ioannou, GN; Shen, H; Song, X; Stevenson, HL; Wang, J; Yoo, SY; Yoo, W, 2017) |
| "For successful treatment for nonalcoholic steatohepatitis (NASH), it may be important to treat the individual causative factors." | 1.46 | Branched-chain amino acids alleviate hepatic steatosis and liver injury in choline-deficient high-fat diet induced NASH mice. ( Feng, GG; Goto, H; Hayashi, K; Hirooka, Y; Honda, T; Ishigami, M; Ishikawa, T; Ishizu, Y; Katano, Y; Kitaura, Y; Kohama, T; Kuzuya, T; Lingyun, M; Luo, F; Nakano, I; Shimomura, Y, 2017) |
| " While the rich bioavailability research of curcumin, BDMC is the poor studies." | 1.43 | Hepatoprotective Effect and Synergism of Bisdemethoycurcumin against MCD Diet-Induced Nonalcoholic Fatty Liver Disease in Mice. ( Ahn, YS; Cha, SW; Han, SH; Kang, OH; Kim, SB; Kong, R; Kwon, DY; Lee, YS; Seo, YS, 2016) |
| "Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease worldwide." | 1.43 | Regulation of Inflammation by IL-17A and IL-17F Modulates Non-Alcoholic Fatty Liver Disease Pathogenesis. ( Cappelletti, M; Divanovic, S; Dong, C; Giles, DA; Huppert, SS; Iwakura, Y; Moreno-Fernandez, ME; Shanmukhappa, SK; Stankiewicz, TE, 2016) |
| "Non-alcoholic fatty liver disease (NAFLD) affects a large proportion of the US population and is considered to be a metabolic predisposition to liver cancer." | 1.43 | NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis. ( Egger, M; Eggert, T; ElGindi, M; Felsher, DW; Greten, TF; Han, M; Heikenwalder, M; Jin, P; Kapoor, V; Kesarwala, AH; Kleiner, DE; Luo, J; Ma, C; McVicar, DW; Medina-Echeverz, J; Stroncek, DF; Terabe, M; Thornton, AM; Weber, A; Zhang, H, 2016) |
| "Nonalcoholic fatty liver disease (NAFLD) is a major health problem and a leading cause of chronic liver disease in the United States and Western countries." | 1.43 | Status of hepatic DNA methylome predetermines and modulates the severity of non-alcoholic fatty liver injury in mice. ( Beland, FA; Fuscoe, JC; Han, T; Pogribny, IP; Ross, SA; Tryndyak, VP, 2016) |
| "Nonalcoholic fatty liver disease (NAFLD) refers to hepatic pathologies, including simple fatty liver (SFL), nonalcoholic steatohepatitis (NASH), fibrosis, and cirrhosis, that may progress to hepatocellular carcinoma." | 1.43 | Effects of Nonalcoholic Fatty Liver Disease on Hepatic CYP2B1 and in Vivo Bupropion Disposition in Rats Fed a High-Fat or Methionine/Choline-Deficient Diet. ( Cho, HJ; Cho, SJ; Chong, S; Chung, SJ; Kang, IM; Kim, DD; Kim, SB; Lee, JI; Yoon, IS, 2016) |
| "Nonalcoholic steatohepatitis is a variable in drug disposition, yet the impact on renal transport processes has yet to be fully understood." | 1.43 | Effect of nonalcoholic steatohepatitis on renal filtration and secretion of adefovir. ( Cherrington, NJ; Clarke, JD; Dzierlenga, AL; Goedken, M; Klein, DM; Laho, T; Li, H; Micuda, S, 2016) |
| "Metformin is an antihyperglycemic drug that is widely prescribed for type 2 diabetes mellitus and is currently being investigated for the treatment of nonalcoholic steatohepatitis (NASH)." | 1.42 | Mechanism of Altered Metformin Distribution in Nonalcoholic Steatohepatitis. ( Cherrington, NJ; Clarke, JD; Dzierlenga, AL; Goedken, MJ; Li, H; Nelson, NR; Werts, S, 2015) |
| "Although therapeutic intervention for nonalcoholic steatohepatitis (NASH) at an early stage is important owing to the progressive nature of the disease, diagnosis using noninvasive methods remains difficult." | 1.40 | Oral choline tolerance test as a novel noninvasive method for predicting nonalcoholic steatohepatitis. ( Fujita, K; Imajo, K; Kessoku, T; Kirikoshi, H; Mawatari, H; Nakajima, A; Nozaki, Y; Ogawa, Y; Saito, S; Sekino, Y; Shinohara, Y; Taguri, M; Takahashi, J; Tomeno, W; Toshima, G; Wada, K; Yoneda, M, 2014) |
| "Development of nonalcoholic fatty liver disease (NAFLD) occurs through initial steatosis and subsequent oxidative stress." | 1.40 | The effects of α-lipoic acid on liver oxidative stress and free fatty acid composition in methionine-choline deficient diet-induced NAFLD. ( de Luka, S; Ethuričić, I; Jorgačević, B; Mladenović, D; Ninković, M; Radosavljević, TS; Sobajić, S; Stanković, MN; Vukicevic, RJ, 2014) |
| "Nonalcoholic steatohepatitis (NASH), a progressive stage of nonalcoholic fatty liver disease (NAFLD), is characterized by steatosis with inflammation." | 1.40 | Prevention of nonalcoholic steatohepatitis in rats by two manganese-salen complexes. ( Rezazadeh, A; Yazdanparast, R, 2014) |
| "This pathway is down-regulated in nonalcoholic fatty liver disease." | 1.40 | GH administration rescues fatty liver regeneration impairment by restoring GH/EGFR pathway deficiency. ( Baud, V; Billot, K; Collin de l'Hortet, A; Fauveau, V; Gilgenkrantz, H; Guidotti, JE; Helmy, N; Prip-Buus, C; Vons, C; Zerrad-Saadi, A; Ziol, M, 2014) |
| "Thereafter, liver injury, liver fibrosis and hepatocellular apoptosis were quantified in liver sections." | 1.40 | Caspase 3 inactivation protects against hepatic cell death and ameliorates fibrogenesis in a diet-induced NASH model. ( Berk, M; Dixon, L; Feldstein, AE; Inzaugarat, ME; Papouchado, BG; Povero, D; Thapaliya, S; Wree, A, 2014) |
| "Non-alcoholic fatty liver disease (NAFLD) is the commonest form of chronic liver disease in developed countries." | 1.40 | Metabolomics-based search for therapeutic agents for non-alcoholic steatohepatitis. ( Azuma, T; Hoshi, N; Kawano, Y; Minami, A; Nishiumi, S; Terashima, Y; Yoshida, M, 2014) |
| "To generate the NAFLD model, Sprague-Dawley rats were administered a high‑fat diet and following 12 weeks of model construction, rats were orally treated with a positive control drug and different doses of TARAP daily for 28 days." | 1.40 | Protective effects and mechanisms of total alkaloids of Rubus alceaefolius Poir on non‑alcoholic fatty liver disease in rats. ( Hong, Z; Liu, Y; Peng, J; Wu, J; Zhao, J; Zheng, H; Zheng, Y, 2014) |
| "In parallel with the elevation in AR, steatohepatitis was observed in MCD diet-fed mice, and this diet-induced steatohepatitis was significantly attenuated by lentiviral-mediated knock-down of the AR gene." | 1.39 | Aldose reductase is involved in the development of murine diet-induced nonalcoholic steatohepatitis. ( Chen, J; Chen, W; Deng, T; Lin, J; Qiu, L; Shi, D; Yang, J; Yang, JY; Ying, M, 2013) |
| "NAFLD is linked to a wide spectrum of diseases including obesity and diabetes that are increasingly prevalent in Western populations." | 1.38 | Hepatic ratio of phosphatidylcholine to phosphatidylethanolamine predicts survival after partial hepatectomy in mice. ( Chaba, T; Jacobs, RL; Ling, J; Vance, DE; Zhu, LF, 2012) |
| "These data indicate that low CMKLR1 in NAFLD may partly result from reduced adiponectin activity." | 1.38 | Adiponectin upregulates hepatocyte CMKLR1 which is reduced in human fatty liver. ( Bauer, S; Buechler, C; Eisinger, K; Hellerbrand, C; Higuchi, A; Schäffler, A; Walsh, K; Walter, R; Wanninger, J; Weiss, TS, 2012) |
| "Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome and the leading cause of chronic liver disease in the Western world." | 1.38 | Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. ( Camporez, JP; Eisenbarth, SC; Elinav, E; Flavell, RA; Gordon, JI; Hao, L; Henao-Mejia, J; Hoffman, HM; Jin, C; Jurczak, MJ; Kau, AL; Mehal, WZ; Shulman, GI; Strowig, T; Thaiss, CA, 2012) |
| "Hyperleptinaemia plays an important role in hyper-responsiveness to MTX in NASH-cirrhotic rat livers with portal hypertension." | 1.38 | Kupffer cell depletion attenuates leptin-mediated methoxamine-stimulated portal perfusion pressure and thromboxane A2 release in a rodent model of NASH-cirrhosis. ( Hou, MC; Huang, YT; Lee, FY; Lee, SD; Lin, HC; Tsai, TH; Yang, YY, 2012) |
| "Quercetin (50 mg/kg) was given by oral route daily." | 1.38 | Quercetin treatment ameliorates inflammation and fibrosis in mice with nonalcoholic steatohepatitis. ( González-Gallego, J; Marcolin, E; Marroni, N; San-Miguel, B; Tieppo, J; Tuñón, MJ; Vallejo, D, 2012) |
| "The mechanisms triggering nonalcoholic steatohepatitis (NASH) remain poorly defined." | 1.38 | Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factor-α production. ( Hahn, YS; Landes, SG; Nguyen, V; Novobrantseva, TI; Tosello-Trampont, AC, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 94 (46.77) | 24.3611 |
| 2020's | 107 (53.23) | 2.80 |
| Authors | Studies |
|---|---|
| Ohtani, N | 1 |
| Hara, E | 1 |
| Zhang, C | 1 |
| Zhang, B | 2 |
| Chen, A | 1 |
| Yin, Q | 1 |
| Wang, H | 6 |
| Lee, N | 1 |
| Heo, YJ | 1 |
| Choi, SE | 1 |
| Jeon, JY | 1 |
| Han, SJ | 1 |
| Kim, DJ | 1 |
| Kang, Y | 1 |
| Lee, KW | 1 |
| Kim, HJ | 2 |
| Wen, F | 1 |
| Bian, D | 1 |
| Wu, X | 3 |
| Liu, R | 1 |
| Wang, C | 4 |
| Gan, J | 1 |
| Herrera-Marcos, LV | 1 |
| Martínez-Beamonte, R | 1 |
| Macías-Herranz, M | 1 |
| Arnal, C | 1 |
| Barranquero, C | 1 |
| Puente-Lanzarote, JJ | 1 |
| Gascón, S | 1 |
| Herrero-Continente, T | 1 |
| Gonzalo-Romeo, G | 1 |
| Alastrué-Vera, V | 1 |
| Gutiérrez-Blázquez, D | 1 |
| Lou-Bonafonte, JM | 1 |
| Surra, JC | 1 |
| Rodríguez-Yoldi, MJ | 1 |
| García-Gil, A | 1 |
| Güemes, A | 1 |
| Osada, J | 1 |
| Alshawsh, MA | 1 |
| Alsalahi, A | 1 |
| Alshehade, SA | 1 |
| Saghir, SAM | 1 |
| Ahmeda, AF | 1 |
| Al Zarzour, RH | 1 |
| Mahmoud, AM | 1 |
| Wan, Q | 1 |
| Peng, H | 1 |
| Lyu, J | 1 |
| Liu, F | 3 |
| Cheng, C | 1 |
| Qiao, Y | 1 |
| Deng, J | 1 |
| Zheng, H | 4 |
| Wang, Y | 6 |
| Zou, C | 1 |
| Liu, X | 2 |
| Xin, SL | 1 |
| Yu, YY | 1 |
| Zhao, M | 2 |
| Ma, L | 3 |
| Honda, T | 3 |
| Kato, A | 2 |
| Ohshiro, T | 1 |
| Yokoyama, S | 2 |
| Yamamoto, K | 2 |
| Ito, T | 1 |
| Imai, N | 1 |
| Ishizu, Y | 3 |
| Nakamura, M | 1 |
| Kawashima, H | 1 |
| Tsuji, NM | 1 |
| Ishigami, M | 3 |
| Fujishiro, M | 1 |
| Miguel, FM | 1 |
| Picada, JN | 1 |
| da Silva, JB | 1 |
| Schemitt, EG | 1 |
| Colares, JR | 1 |
| Hartmann, RM | 1 |
| Marroni, CA | 1 |
| Marroni, NP | 1 |
| Miao, H | 1 |
| Ouyang, H | 1 |
| Guo, Q | 1 |
| Wei, M | 1 |
| Lu, B | 2 |
| Kai, G | 1 |
| Ji, L | 1 |
| Enomoto, M | 1 |
| Kaji, K | 1 |
| Nishimura, N | 1 |
| Fujimoto, Y | 1 |
| Murata, K | 1 |
| Takeda, S | 1 |
| Tsuji, Y | 1 |
| Fujinaga, Y | 1 |
| Takaya, H | 1 |
| Kawaratani, H | 1 |
| Namisaki, T | 1 |
| Akahane, T | 1 |
| Yoshiji, H | 1 |
| Ding, N | 2 |
| Wang, K | 2 |
| Jiang, H | 1 |
| Yang, M | 1 |
| Zhang, L | 4 |
| Fan, X | 1 |
| Zou, Q | 1 |
| Yu, J | 1 |
| Dong, H | 2 |
| Cheng, S | 1 |
| Xu, Y | 4 |
| Liu, J | 5 |
| Zhu, B | 1 |
| Li, H | 10 |
| Guo, X | 2 |
| Wu, C | 5 |
| Wang, F | 4 |
| Li, Q | 6 |
| Xie, L | 4 |
| Glaser, S | 2 |
| Francis, H | 2 |
| Alpini, G | 2 |
| Tan, YY | 1 |
| Yue, SR | 1 |
| Lu, AP | 1 |
| Ji, G | 3 |
| Liu, BC | 1 |
| Wang, RR | 1 |
| Lee, GR | 1 |
| Lee, HI | 1 |
| Kim, N | 1 |
| Lee, J | 1 |
| Kwon, M | 1 |
| Kang, YH | 1 |
| Song, HJ | 1 |
| Yeo, CY | 1 |
| Jeong, W | 1 |
| Palladini, G | 1 |
| Di Pasqua, LG | 2 |
| Cagna, M | 1 |
| Croce, AC | 2 |
| Perlini, S | 1 |
| Mannucci, B | 1 |
| Profumo, A | 1 |
| Ferrigno, A | 2 |
| Vairetti, M | 2 |
| Kaufmann, B | 1 |
| Kui, L | 1 |
| Reca, A | 1 |
| Leszczynska, A | 1 |
| Kim, AD | 1 |
| Booshehri, LM | 1 |
| Wree, A | 2 |
| Friess, H | 1 |
| Hartmann, D | 1 |
| Broderick, L | 1 |
| Hoffman, HM | 3 |
| Feldstein, AE | 3 |
| Seike, T | 1 |
| Boontem, P | 1 |
| Yanagi, M | 1 |
| Li, S | 1 |
| Kido, H | 1 |
| Yamamiya, D | 1 |
| Nakagawa, H | 1 |
| Okada, H | 1 |
| Yamashita, T | 1 |
| Harada, K | 1 |
| Kikuchi, M | 1 |
| Shiraishi, Y | 1 |
| Ozaki, N | 1 |
| Kaneko, S | 1 |
| Yamashima, T | 1 |
| Mizukoshi, E | 1 |
| Zhang, Y | 3 |
| Ye, S | 1 |
| Lu, W | 1 |
| Zhong, J | 1 |
| Leng, Y | 1 |
| Yang, T | 1 |
| Luo, J | 2 |
| Xu, W | 1 |
| Zhang, H | 4 |
| Kong, L | 1 |
| Nagumalli, SK | 1 |
| Willett, RA | 1 |
| de Conti, A | 2 |
| Tryndyak, VP | 2 |
| Avigan, MI | 1 |
| da Costa, GG | 1 |
| Beland, FA | 3 |
| Rusyn, I | 2 |
| Pogribny, IP | 3 |
| Hu, PX | 1 |
| Sheng, MY | 1 |
| Liu, YP | 1 |
| Zhang, CQ | 1 |
| Qiu, H | 1 |
| Song, E | 1 |
| Hu, Y | 1 |
| Li, T | 1 |
| Ku, KC | 1 |
| Cheung, BMY | 1 |
| Cheong, LY | 1 |
| Wang, Q | 2 |
| Hoo, RLC | 1 |
| Xu, A | 1 |
| Kawahara, A | 1 |
| Kanno, K | 2 |
| Yonezawa, S | 1 |
| Otani, Y | 1 |
| Kobayashi, T | 1 |
| Tazuma, S | 2 |
| Ito, M | 1 |
| Hymel, E | 3 |
| Vlock, E | 1 |
| Fisher, KW | 3 |
| Farazi, PA | 3 |
| Kong, W | 1 |
| Tang, Y | 1 |
| Liu, L | 3 |
| Zhang, G | 1 |
| Liu, Y | 8 |
| Heredia, JE | 1 |
| Sorenson, C | 1 |
| Flanagan, S | 1 |
| Nunez, V | 1 |
| Jones, C | 1 |
| Martzall, A | 1 |
| Leong, L | 1 |
| Martinez, AP | 1 |
| Scherl, A | 1 |
| Brightbill, HD | 1 |
| Ghilardi, N | 1 |
| Wu, A | 1 |
| Cai, J | 1 |
| She, ZG | 1 |
| Hu, J | 2 |
| Zheng, Y | 3 |
| Ying, H | 1 |
| Ma, H | 1 |
| Li, L | 2 |
| Zhao, Y | 3 |
| He, L | 1 |
| Wang, X | 6 |
| Ding, Z | 1 |
| Cheng, H | 1 |
| Bily, D | 1 |
| Zhang, K | 1 |
| Xu, L | 2 |
| Zhang, O | 1 |
| Zhang, F | 1 |
| Song, M | 1 |
| Ma, M | 1 |
| Ding, R | 1 |
| Li, D | 2 |
| Dong, Z | 1 |
| Jin, S | 1 |
| Han, W | 1 |
| Ding, C | 1 |
| Lützhøft, DO | 3 |
| Sinioja, T | 3 |
| Christoffersen, BØ | 3 |
| Jakobsen, RR | 3 |
| Geng, D | 3 |
| Ahmad, HFB | 3 |
| Straarup, EM | 3 |
| Pedersen, KM | 3 |
| Kot, W | 3 |
| Pedersen, HD | 3 |
| Cirera, S | 3 |
| Hyötyläinen, T | 3 |
| Nielsen, DS | 3 |
| Hansen, AK | 3 |
| Bai, ZY | 2 |
| Luo, Z | 2 |
| Hogstrand, C | 2 |
| Wang, LJ | 3 |
| Song, YF | 2 |
| Yan, M | 1 |
| Man, S | 1 |
| Liang, Y | 2 |
| Guo, L | 2 |
| Huang, L | 2 |
| Gao, W | 2 |
| Lin, D | 1 |
| Sun, Q | 1 |
| Liu, Z | 2 |
| Pan, J | 1 |
| Zhu, J | 1 |
| Wang, S | 2 |
| Jia, S | 1 |
| Zheng, M | 1 |
| Li, X | 2 |
| Gong, F | 1 |
| Aljobaily, N | 1 |
| Krutsinger, K | 1 |
| Viereckl, MJ | 1 |
| Joly, R | 1 |
| Menlove, B | 1 |
| Cone, B | 1 |
| Suppes, A | 1 |
| Han, Y | 1 |
| Wu, J | 2 |
| Qi, S | 1 |
| Liu, W | 2 |
| Liu, P | 2 |
| Shi, S | 1 |
| Zhang, Q | 3 |
| Giri, SR | 1 |
| Bhoi, B | 1 |
| Trivedi, C | 1 |
| Rath, A | 1 |
| Rathod, R | 1 |
| Sharma, A | 1 |
| Ranvir, R | 1 |
| Kadam, S | 1 |
| Ingale, K | 1 |
| Patel, H | 1 |
| Nyska, A | 1 |
| Jain, MR | 1 |
| Gayban, AJB | 1 |
| Souza, LAC | 1 |
| Cooper, SG | 1 |
| Regalado, E | 1 |
| Kleemann, R | 1 |
| Feng Earley, Y | 1 |
| Rein-Fischboeck, L | 3 |
| Pohl, R | 3 |
| Haberl, EM | 3 |
| Mages, W | 1 |
| Girke, P | 1 |
| Liebisch, G | 2 |
| Krautbauer, S | 3 |
| Buechler, C | 4 |
| Huang, X | 2 |
| Chen, Q | 1 |
| Fan, Y | 1 |
| Yang, R | 1 |
| Gong, G | 1 |
| Yan, C | 1 |
| Song, Y | 2 |
| Xi, S | 1 |
| Huang, Y | 1 |
| Xu, H | 2 |
| Zhen, Q | 1 |
| Liang, Q | 1 |
| Lu, Z | 1 |
| Bian, C | 1 |
| Zhao, X | 1 |
| Lv, S | 1 |
| Zhang, Z | 1 |
| Su, X | 1 |
| Li, W | 1 |
| Pan, B | 1 |
| Guo, C | 1 |
| Chen, R | 3 |
| Fan, W | 1 |
| Zhang, X | 4 |
| Qu, X | 1 |
| Zhu, M | 1 |
| Zhao, Z | 1 |
| Dang, Y | 1 |
| Li, F | 2 |
| Zhou, W | 1 |
| Wu, S | 2 |
| Wu, Y | 2 |
| Lin, L | 1 |
| Ruan, C | 1 |
| Du, H | 1 |
| Luo, X | 1 |
| Korsmo, HW | 1 |
| Kadam, I | 1 |
| Reaz, A | 1 |
| Bretter, R | 1 |
| Saxena, A | 1 |
| Johnson, CH | 1 |
| Caviglia, JM | 1 |
| Jiang, X | 1 |
| Oates, JR | 1 |
| Sawada, K | 1 |
| Giles, DA | 2 |
| Alarcon, PC | 1 |
| Damen, MSMA | 1 |
| Szabo, S | 1 |
| Stankiewicz, TE | 2 |
| Moreno-Fernandez, ME | 2 |
| Divanovic, S | 2 |
| Nakamura, S | 1 |
| Nakamura, K | 1 |
| Yokoi, Y | 1 |
| Shimizu, Y | 1 |
| Ohira, S | 1 |
| Hagiwara, M | 1 |
| Song, Z | 1 |
| Gan, L | 1 |
| Aizawa, T | 1 |
| Hashimoto, D | 1 |
| Teshima, T | 1 |
| Ouellette, AJ | 1 |
| Ayabe, T | 1 |
| Liu, H | 1 |
| Jiang, N | 1 |
| Kuang, G | 1 |
| Gong, X | 1 |
| Yin, X | 1 |
| Wan, J | 1 |
| Mohammed, S | 1 |
| Thadathil, N | 1 |
| Ohene-Marfo, P | 1 |
| Tran, AL | 1 |
| Van Der Veldt, M | 1 |
| Georgescu, C | 1 |
| Oh, S | 1 |
| Nicklas, EH | 1 |
| Wang, D | 1 |
| Haritha, NH | 1 |
| Luo, W | 2 |
| Janknecht, R | 1 |
| Miller, BF | 1 |
| Wren, JD | 1 |
| Freeman, WM | 1 |
| Deepa, SS | 1 |
| Timaná, J | 1 |
| Chahuara, H | 1 |
| Basavarajappa, L | 1 |
| Basarab, A | 1 |
| Hoyt, K | 1 |
| Lavarello, R | 1 |
| Chu, H | 1 |
| Zhang, W | 1 |
| Tan, Y | 1 |
| Diao, Z | 1 |
| Li, P | 4 |
| Sun, J | 1 |
| Yang, K | 1 |
| Xie, C | 1 |
| Hua, Q | 1 |
| Xu, X | 1 |
| Povero, D | 2 |
| Lazic, M | 1 |
| McBride, C | 1 |
| Ambrus-Aikelin, G | 1 |
| Stansfield, R | 1 |
| Johnson, CD | 1 |
| Santini, AM | 1 |
| Pranadinata, RF | 1 |
| McGeough, MD | 1 |
| Stafford, JA | 1 |
| Veal, JM | 1 |
| Bain, G | 1 |
| Stols-Gonçalves, D | 1 |
| Mak, AL | 1 |
| Madsen, MS | 1 |
| van der Vossen, EWJ | 1 |
| Bruinstroop, E | 1 |
| Henneman, P | 1 |
| Mol, F | 1 |
| Scheithauer, TPM | 1 |
| Smits, L | 1 |
| Witjes, J | 1 |
| Meijnikman, AS | 1 |
| Verheij, J | 1 |
| Nieuwdorp, M | 1 |
| Holleboom, AG | 1 |
| Levin, E | 1 |
| Campagnoli, LIM | 1 |
| Barbieri, A | 1 |
| Marchesi, N | 1 |
| Pascale, A | 1 |
| DiStefano, JK | 1 |
| Hammoutene, A | 1 |
| Tanguy, M | 1 |
| Calmels, M | 1 |
| Pravisani, R | 1 |
| Albuquerque, M | 1 |
| Casteleyn, C | 1 |
| Slimani, L | 1 |
| Sadoine, J | 1 |
| Boulanger, CM | 1 |
| Paradis, V | 1 |
| Gilgenkrantz, H | 2 |
| Rautou, PE | 1 |
| Zhou, H | 1 |
| Niu, B | 1 |
| Chu, W | 1 |
| Zhou, Y | 1 |
| Chen, Z | 1 |
| Mi, Y | 1 |
| Ma, K | 1 |
| Hu, X | 1 |
| Nambu, K | 1 |
| Ueda, D | 1 |
| Ichimaru, N | 1 |
| Fujino, M | 1 |
| Li, XK | 1 |
| Rodrigues, PM | 1 |
| Afonso, MB | 1 |
| Simão, AL | 1 |
| Islam, T | 1 |
| Gaspar, MM | 1 |
| O'Rourke, CJ | 1 |
| Lewinska, M | 1 |
| Andersen, JB | 1 |
| Arretxe, E | 1 |
| Alonso, C | 2 |
| Santos-Laso, Á | 1 |
| Izquierdo-Sanchez, L | 1 |
| Jimenez-Agüero, R | 1 |
| Eizaguirre, E | 1 |
| Bujanda, L | 1 |
| Pareja, MJ | 1 |
| Prip-Buus, C | 2 |
| Banales, JM | 1 |
| Rodrigues, CMP | 1 |
| Castro, RE | 1 |
| Suzuki-Kemuriyama, N | 3 |
| Abe, A | 3 |
| Nakane, S | 2 |
| Yuki, M | 3 |
| Miyajima, K | 3 |
| Nakae, D | 3 |
| Choi, J | 1 |
| Choi, H | 1 |
| Chung, J | 1 |
| Chai, C | 1 |
| Chen, L | 1 |
| Deng, MG | 1 |
| Nie, JQ | 1 |
| Yang, H | 2 |
| Kim, J | 1 |
| Lee, Y | 1 |
| Kim, SH | 1 |
| Do, IG | 1 |
| Park, CY | 1 |
| Fang, Y | 1 |
| Qian, C | 1 |
| Chen, J | 3 |
| Zuo, W | 1 |
| Lin, J | 2 |
| Liang, G | 1 |
| Lee, YK | 1 |
| Park, JE | 1 |
| Lee, M | 1 |
| Mifflin, R | 1 |
| Novak, R | 1 |
| Hardwick, JP | 1 |
| Liang, C | 1 |
| Gao, S | 1 |
| Gao, J | 2 |
| Kim, DY | 1 |
| Park, JY | 1 |
| Gee, HY | 1 |
| Carvajal, S | 1 |
| Perramón, M | 1 |
| Oró, D | 1 |
| Casals, E | 1 |
| Fernández-Varo, G | 1 |
| Casals, G | 1 |
| Parra, M | 1 |
| González de la Presa, B | 1 |
| Ribera, J | 1 |
| Pastor, Ó | 1 |
| Morales-Ruíz, M | 1 |
| Puntes, V | 1 |
| Jiménez, W | 1 |
| Cerletti, C | 1 |
| Colucci, M | 1 |
| Storto, M | 1 |
| Semeraro, F | 1 |
| Ammollo, CT | 1 |
| Incampo, F | 1 |
| Costanzo, S | 1 |
| De Bartolomeo, G | 1 |
| Portincasa, P | 1 |
| Barone, M | 1 |
| Di Castelnuovo, A | 1 |
| Semeraro, N | 1 |
| Iacoviello, L | 1 |
| de Gaetano, G | 1 |
| Wang, XM | 1 |
| Wang, XY | 1 |
| Huang, YM | 1 |
| Chen, X | 2 |
| Lü, MH | 1 |
| Shi, L | 1 |
| Li, CP | 1 |
| Zhu, H | 1 |
| Ge, K | 1 |
| Lu, J | 3 |
| Jia, C | 1 |
| Carril, E | 1 |
| Valdecantos, MP | 2 |
| Lanzón, B | 1 |
| Angulo, S | 1 |
| Valverde, ÁM | 2 |
| Godzien, J | 1 |
| Rupérez, FJ | 1 |
| Montandon, SA | 2 |
| Somm, E | 2 |
| Loizides-Mangold, U | 2 |
| de Vito, C | 2 |
| Dibner, C | 2 |
| Jornayvaz, FR | 2 |
| Radziejewska, A | 1 |
| Muzsik, A | 1 |
| Milagro, FI | 2 |
| Martínez, JA | 2 |
| Chmurzynska, A | 1 |
| Hernandez, GV | 1 |
| Smith, VA | 1 |
| Melnyk, M | 1 |
| Burd, MA | 1 |
| Sprayberry, KA | 1 |
| Edwards, MS | 1 |
| Peterson, DG | 1 |
| Bennet, DC | 1 |
| Fanter, RK | 1 |
| Columbus, DA | 1 |
| Steibel, JP | 1 |
| Glanz, H | 1 |
| Immoos, C | 1 |
| Rice, MS | 1 |
| Santiago-Rodriguez, TM | 1 |
| Blank, J | 1 |
| VanderKelen, JJ | 1 |
| Kitts, CL | 1 |
| Piccolo, BD | 1 |
| La Frano, MR | 1 |
| Burrin, DG | 1 |
| Maj, M | 1 |
| Manjarin, R | 1 |
| Simon, J | 1 |
| Nuñez-García, M | 1 |
| Fernández-Tussy, P | 1 |
| Barbier-Torres, L | 1 |
| Fernández-Ramos, D | 1 |
| Gómez-Santos, B | 1 |
| Buqué, X | 1 |
| Lopitz-Otsoa, F | 1 |
| Goikoetxea-Usandizaga, N | 1 |
| Serrano-Macia, M | 1 |
| Rodriguez-Agudo, R | 1 |
| Bizkarguenaga, M | 1 |
| Zubiete-Franco, I | 1 |
| Gutiérrez-de Juan, V | 1 |
| Cabrera, D | 1 |
| Iruzubieta, P | 1 |
| Romero-Gomez, M | 2 |
| van Liempd, S | 1 |
| Castro, A | 1 |
| Nogueiras, R | 1 |
| Varela-Rey, M | 1 |
| Falcón-Pérez, JM | 1 |
| Villa, E | 1 |
| Crespo, J | 1 |
| Lu, SC | 1 |
| Mato, JM | 1 |
| Aspichueta, P | 1 |
| Delgado, TC | 1 |
| Martínez-Chantar, ML | 1 |
| Yamauchi, A | 1 |
| Tone, T | 1 |
| Toledo, A | 1 |
| Igarashi, K | 1 |
| Sugimoto, K | 1 |
| Miyai, H | 1 |
| Deng, D | 1 |
| Nakamura, J | 1 |
| Lim, HS | 1 |
| Kaku, T | 1 |
| Hirano, E | 1 |
| Shindo, T | 1 |
| Wang, TX | 1 |
| Li, Y | 5 |
| Sun, T | 1 |
| Zang, S | 1 |
| Guan, KL | 1 |
| Xiong, Y | 1 |
| Yuan, HX | 1 |
| Yasuda, D | 1 |
| Torii, H | 1 |
| Shimizu, R | 1 |
| Hiraoka, Y | 1 |
| Kume, N | 1 |
| Yang, G | 2 |
| Jang, JH | 1 |
| Kim, SW | 1 |
| Han, SH | 2 |
| Ma, KH | 1 |
| Jang, JK | 1 |
| Kang, HC | 1 |
| Cho, YY | 1 |
| Lee, HS | 1 |
| Lee, JY | 1 |
| Cui, A | 1 |
| Li, J | 3 |
| Ji, S | 1 |
| Ma, F | 1 |
| Wang, G | 1 |
| Xue, Y | 1 |
| Han, J | 1 |
| Tai, P | 1 |
| Wang, T | 2 |
| Ma, X | 1 |
| Zanieri, F | 1 |
| Levi, A | 1 |
| Montefusco, D | 1 |
| Longato, L | 1 |
| De Chiara, F | 1 |
| Frenguelli, L | 1 |
| Omenetti, S | 1 |
| Andreola, F | 1 |
| Luong, TV | 1 |
| Massey, V | 1 |
| Caballeria, J | 1 |
| Fondevila, C | 1 |
| Shanmugavelandy, SS | 1 |
| Fox, T | 1 |
| Mazza, G | 1 |
| Argemi, J | 1 |
| Bataller, R | 1 |
| Cowart, LA | 1 |
| Kester, M | 1 |
| Pinzani, M | 1 |
| Rombouts, K | 1 |
| Takatani, N | 1 |
| Kono, Y | 1 |
| Beppu, F | 1 |
| Okamatsu-Ogura, Y | 1 |
| Yamano, Y | 1 |
| Miyashita, K | 1 |
| Hosokawa, M | 1 |
| Mori, Y | 1 |
| Kawakami, Y | 1 |
| Kanzaki, K | 1 |
| Otsuki, A | 1 |
| Kimura, Y | 3 |
| Kanji, H | 1 |
| Tanaka, R | 1 |
| Tsukayama, I | 1 |
| Hojo, N | 1 |
| Suzuki-Yamamoto, T | 1 |
| Kawakami, T | 1 |
| Takahashi, Y | 1 |
| Ke, Z | 1 |
| Tan, S | 1 |
| Chen, H | 1 |
| Zhou, Z | 1 |
| Huang, C | 1 |
| Micheli, L | 1 |
| Pacini, A | 1 |
| Di Cesare Mannelli, L | 1 |
| Trallori, E | 1 |
| D'Ambrosio, R | 1 |
| Bianchini, C | 1 |
| Lampertico, P | 1 |
| Ghelardini, C | 1 |
| Leclère, PS | 1 |
| Rousseau, D | 1 |
| Patouraux, S | 1 |
| Guérin, S | 1 |
| Bonnafous, S | 1 |
| Gréchez-Cassiau, A | 1 |
| Ruberto, AA | 1 |
| Luci, C | 1 |
| Subramaniam, M | 1 |
| Tran, A | 1 |
| Delaunay, F | 1 |
| Gual, P | 1 |
| Teboul, M | 1 |
| Gaïa, N | 1 |
| Lazarevic, V | 1 |
| Perroud, E | 1 |
| Bochaton-Piallat, ML | 1 |
| Schrenzel, J | 1 |
| Arias, N | 1 |
| Arboleya, S | 1 |
| Allison, J | 1 |
| Kaliszewska, A | 1 |
| Higarza, SG | 1 |
| Gueimonde, M | 1 |
| Arias, JL | 1 |
| Vesković, M | 1 |
| Labudović-Borović, M | 1 |
| Mladenović, D | 2 |
| Jadžić, J | 1 |
| Jorgačević, B | 3 |
| Vukićević, D | 1 |
| Vučević, D | 1 |
| Radosavljević, T | 1 |
| León-Mimila, P | 1 |
| Villamil-Ramírez, H | 1 |
| Li, XS | 1 |
| Shih, DM | 1 |
| Hui, ST | 1 |
| Ocampo-Medina, E | 1 |
| López-Contreras, B | 1 |
| Morán-Ramos, S | 1 |
| Olivares-Arevalo, M | 1 |
| Grandini-Rosales, P | 1 |
| Macías-Kauffer, L | 1 |
| González-González, I | 1 |
| Hernández-Pando, R | 1 |
| Gómez-Pérez, F | 1 |
| Campos-Pérez, F | 1 |
| Aguilar-Salinas, C | 1 |
| Larrieta-Carrasco, E | 1 |
| Villarreal-Molina, T | 1 |
| Wang, Z | 2 |
| Lusis, AJ | 1 |
| Hazen, SL | 1 |
| Huertas-Vazquez, A | 1 |
| Canizales-Quinteros, S | 1 |
| Mungamuri, SK | 1 |
| Vijayasarathy, K | 1 |
| Brzezinski, RY | 1 |
| Levin-Kotler, L | 1 |
| Rabin, N | 1 |
| Ovadia-Blechman, Z | 1 |
| Zimmer, Y | 1 |
| Sternfeld, A | 1 |
| Finchelman, JM | 1 |
| Unis, R | 1 |
| Lewis, N | 1 |
| Tepper-Shaihov, O | 1 |
| Naftali-Shani, N | 1 |
| Balint-Lahat, N | 1 |
| Safran, M | 1 |
| Ben-Ari, Z | 1 |
| Grossman, E | 1 |
| Leor, J | 1 |
| Hoffer, O | 1 |
| Bae, CR | 1 |
| Kwon, YG | 1 |
| Höring, M | 1 |
| Uno, K | 2 |
| Ogawa, S | 2 |
| Watanabe, A | 2 |
| Sano, R | 2 |
| Liu, C | 1 |
| Lu, Y | 1 |
| Yang, J | 2 |
| Yao, Y | 1 |
| Yang, YM | 1 |
| Matsuda, M | 1 |
| Seki, E | 1 |
| Gong, MJ | 1 |
| Zhu, CY | 1 |
| Zou, ZJ | 1 |
| Han, B | 1 |
| Huang, P | 1 |
| Komeili-Movahhed, T | 1 |
| Bassirian, M | 1 |
| Changizi, Z | 1 |
| Moslehi, A | 1 |
| Jiang, Q | 1 |
| Liu, B | 1 |
| Li, G | 1 |
| Riedemann, G | 1 |
| Gaitantzi, H | 1 |
| Breitkopf-Heinlein, K | 1 |
| Zeng, A | 1 |
| Ding, H | 1 |
| Xu, K | 1 |
| Zhu, Y | 2 |
| Zhao, H | 1 |
| Lin, K | 1 |
| Ni, J | 1 |
| Wu, G | 1 |
| Tang, H | 1 |
| Cui, S | 1 |
| Pan, XJ | 1 |
| Ge, CL | 1 |
| Guo, YT | 1 |
| Zhang, PF | 1 |
| Yan, TT | 1 |
| Zhou, JY | 1 |
| He, QX | 1 |
| Cheng, LH | 1 |
| Wang, GJ | 1 |
| Hao, HP | 1 |
| Yang, SH | 1 |
| Wu, H | 1 |
| Yi, ZJ | 1 |
| Lai, X | 1 |
| Matthews, DR | 1 |
| Zhou, J | 1 |
| Qin, B | 1 |
| Diao, N | 1 |
| Bai, L | 1 |
| Wankhade, UD | 1 |
| Zhong, Y | 1 |
| Kang, P | 1 |
| Alfaro, M | 1 |
| Chintapalli, SV | 1 |
| Thakali, KM | 1 |
| Shankar, K | 1 |
| Zöhrer, E | 1 |
| Alisi, A | 2 |
| Jahnel, J | 1 |
| Mosca, A | 1 |
| Della Corte, C | 1 |
| Crudele, A | 2 |
| Fauler, G | 1 |
| Nobili, V | 2 |
| Mitsumoto, K | 1 |
| Watanabe, R | 1 |
| Nakao, K | 1 |
| Yonenaka, H | 1 |
| Hashimoto, T | 1 |
| Kato, N | 1 |
| Kumrungsee, T | 1 |
| Yanaka, N | 1 |
| de Faria Ghetti, F | 1 |
| Oliveira, DG | 1 |
| de Oliveira, JM | 1 |
| de Castro Ferreira, LEVV | 1 |
| Cesar, DE | 1 |
| Moreira, APB | 1 |
| Ikawa-Yoshida, A | 1 |
| Matsuo, S | 1 |
| Ohmori, Y | 1 |
| Higashida, A | 1 |
| Kaneko, E | 1 |
| Matsumoto, M | 2 |
| Bagley, BD | 1 |
| Chang, SC | 1 |
| Ehresman, DJ | 1 |
| Eveland, A | 1 |
| Zitzow, JD | 1 |
| Parker, GA | 1 |
| Peters, JM | 1 |
| Wallace, KB | 1 |
| Butenhoff, JL | 1 |
| Devisscher, L | 1 |
| Scott, CL | 1 |
| Lefere, S | 1 |
| Raevens, S | 1 |
| Bogaerts, E | 1 |
| Paridaens, A | 1 |
| Verhelst, X | 1 |
| Geerts, A | 1 |
| Guilliams, M | 1 |
| Van Vlierberghe, H | 1 |
| González-Rodríguez, Á | 1 |
| Rada, P | 1 |
| Addante, A | 1 |
| Barahona, I | 1 |
| Rey, E | 1 |
| Pardo, V | 1 |
| Ruiz, L | 1 |
| Laiglesia, LM | 1 |
| Moreno-Aliaga, MJ | 1 |
| García-Monzón, C | 1 |
| Sánchez, A | 1 |
| Yoo, W | 1 |
| Gjuka, D | 1 |
| Stevenson, HL | 1 |
| Song, X | 1 |
| Shen, H | 1 |
| Yoo, SY | 1 |
| Wang, J | 2 |
| Fallon, M | 1 |
| Ioannou, GN | 1 |
| Harrison, SA | 1 |
| Beretta, L | 1 |
| Alshammari, GM | 1 |
| Balakrishnan, A | 1 |
| Chinnasamy, T | 1 |
| Jing, M | 1 |
| Yang, L | 1 |
| Jin, L | 1 |
| Ding, Y | 1 |
| Cao, Q | 1 |
| Jiang, Y | 1 |
| Han, R | 1 |
| Ma, J | 1 |
| Arai, T | 1 |
| Tanaka, M | 1 |
| Goda, N | 1 |
| Tung, YT | 1 |
| Huang, CZ | 1 |
| Lin, JH | 1 |
| Yen, GC | 1 |
| Xiao, J | 1 |
| Liong, EC | 1 |
| So, KF | 1 |
| Tipoe, GL | 1 |
| Katsyuba, E | 1 |
| Mottis, A | 1 |
| Zietak, M | 1 |
| De Franco, F | 1 |
| van der Velpen, V | 1 |
| Gariani, K | 1 |
| Ryu, D | 1 |
| Cialabrini, L | 1 |
| Matilainen, O | 1 |
| Liscio, P | 1 |
| Giacchè, N | 1 |
| Stokar-Regenscheit, N | 1 |
| Legouis, D | 1 |
| de Seigneux, S | 1 |
| Ivanisevic, J | 1 |
| Raffaelli, N | 1 |
| Schoonjans, K | 1 |
| Pellicciari, R | 1 |
| Auwerx, J | 1 |
| Oh, HS | 1 |
| Cho, W | 1 |
| Tak, SB | 1 |
| Kim, S | 1 |
| Hong, SP | 1 |
| Kim, SO | 1 |
| Zhu, C | 1 |
| Kim, K | 1 |
| Bartolome, A | 1 |
| Salomao, M | 1 |
| Dongiovanni, P | 1 |
| Meroni, M | 1 |
| Graham, MJ | 1 |
| Yates, KP | 1 |
| Diehl, AM | 3 |
| Schwabe, RF | 1 |
| Tabas, I | 1 |
| Valenti, L | 1 |
| Lavine, JE | 2 |
| Pajvani, UB | 1 |
| Ye, C | 1 |
| Cheng, Q | 1 |
| Yao, L | 1 |
| Huang, J | 1 |
| Zou, Z | 1 |
| Yan, J | 1 |
| Ai, D | 1 |
| Schneider, KM | 1 |
| Mohs, A | 1 |
| Kilic, K | 1 |
| Candels, LS | 1 |
| Elfers, C | 1 |
| Bennek, E | 1 |
| Schneider, LB | 1 |
| Heymann, F | 1 |
| Gassler, N | 1 |
| Penders, J | 1 |
| Trautwein, C | 1 |
| Wortmann, SB | 1 |
| Mayr, JA | 1 |
| Bakir, MB | 1 |
| Salama, MA | 1 |
| Refaat, R | 1 |
| Ali, MA | 1 |
| Khalifa, EA | 1 |
| Kamel, MA | 1 |
| Torquato, P | 1 |
| Giusepponi, D | 1 |
| Galarini, R | 1 |
| Bartolini, D | 1 |
| Piroddi, M | 1 |
| Goracci, L | 1 |
| Di Veroli, A | 1 |
| Cruciani, G | 1 |
| Galli, F | 1 |
| Kuzuya, T | 2 |
| Hayashi, K | 2 |
| Hirooka, Y | 2 |
| Goto, H | 2 |
| Clarke, JD | 5 |
| Dzierlenga, A | 1 |
| Arman, T | 1 |
| Toth, E | 1 |
| Lynch, KD | 1 |
| Tian, DD | 1 |
| Goedken, M | 2 |
| Paine, MF | 1 |
| Cherrington, N | 1 |
| Gallego-Durán, R | 1 |
| Álvarez-Amor, L | 1 |
| Gil-Gómez, A | 1 |
| Rojas, Á | 1 |
| Muñoz-Hernández, R | 1 |
| Cádernas-García, A | 1 |
| Maya-Miles, D | 1 |
| Montero-Vallejo, R | 1 |
| Gato, S | 1 |
| Sánchez Torrijos, Y | 1 |
| Ampuero, J | 1 |
| Martín, F | 1 |
| Xiao, F | 1 |
| Ning, Q | 1 |
| Su, Q | 1 |
| Feng, Y | 1 |
| Chen, Y | 1 |
| Yang, B | 1 |
| Lan, Q | 1 |
| Cui, G | 1 |
| Ren, Z | 1 |
| Choi, IC | 1 |
| Leung, GP | 1 |
| Yan, F | 1 |
| Chen, D | 1 |
| Yu, HH | 1 |
| Lee, SMY | 1 |
| Kutanzi, K | 1 |
| Melnyk, S | 1 |
| Tryndyak, V | 1 |
| Montgomery, B | 1 |
| Pogribna, M | 1 |
| Muskhelishvili, L | 1 |
| Latendresse, JR | 1 |
| James, SJ | 1 |
| Imajo, K | 1 |
| Yoneda, M | 1 |
| Fujita, K | 1 |
| Kessoku, T | 1 |
| Tomeno, W | 1 |
| Ogawa, Y | 1 |
| Shinohara, Y | 1 |
| Sekino, Y | 1 |
| Mawatari, H | 1 |
| Nozaki, Y | 1 |
| Kirikoshi, H | 1 |
| Taguri, M | 1 |
| Toshima, G | 1 |
| Takahashi, J | 1 |
| Saito, S | 1 |
| Wada, K | 1 |
| Nakajima, A | 1 |
| Shimozono, R | 1 |
| Asaoka, Y | 1 |
| Yoshizawa, Y | 1 |
| Aoki, T | 1 |
| Noda, H | 1 |
| Yamada, M | 1 |
| Kaino, M | 1 |
| Mochizuki, H | 1 |
| Lee, JT | 1 |
| Pao, LH | 1 |
| Hsiong, CH | 1 |
| Huang, PW | 1 |
| Shih, TY | 1 |
| Yoa-Pu Hu, O | 1 |
| McKee, C | 1 |
| Soeda, J | 1 |
| Asilmaz, E | 1 |
| Sigalla, B | 1 |
| Morgan, M | 1 |
| Sinelli, N | 1 |
| Roskams, T | 1 |
| Oben, JA | 1 |
| Qiu, L | 1 |
| Ying, M | 1 |
| Chen, W | 1 |
| Deng, T | 1 |
| Shi, D | 1 |
| Yang, JY | 1 |
| Stanković, MN | 2 |
| Ninković, M | 1 |
| Ethuričić, I | 1 |
| Sobajić, S | 1 |
| de Luka, S | 1 |
| Vukicevic, RJ | 1 |
| Radosavljević, TS | 2 |
| Al Rajabi, A | 1 |
| Castro, GS | 1 |
| da Silva, RP | 1 |
| Nelson, RC | 1 |
| Thiesen, A | 1 |
| Vannucchi, H | 1 |
| Vine, DF | 1 |
| Proctor, SD | 1 |
| Field, CJ | 1 |
| Curtis, JM | 1 |
| Jacobs, RL | 2 |
| Rezazadeh, A | 1 |
| Yazdanparast, R | 1 |
| Mladenović, DR | 1 |
| Duričić, I | 1 |
| Šobajić, SS | 1 |
| Timić, J | 1 |
| Aleksić, V | 1 |
| Vučević, DB | 1 |
| Ješić-Vukićević, R | 1 |
| Jha, P | 1 |
| Knopf, A | 1 |
| Koefeler, H | 1 |
| Mueller, M | 1 |
| Lackner, C | 1 |
| Hoefler, G | 1 |
| Claudel, T | 1 |
| Trauner, M | 1 |
| Hardwick, RN | 1 |
| Lake, AD | 1 |
| Lickteig, AJ | 1 |
| Goedken, MJ | 2 |
| Klaassen, CD | 1 |
| Cherrington, NJ | 4 |
| Collin de l'Hortet, A | 1 |
| Zerrad-Saadi, A | 1 |
| Fauveau, V | 1 |
| Helmy, N | 1 |
| Ziol, M | 1 |
| Vons, C | 1 |
| Billot, K | 1 |
| Baud, V | 1 |
| Guidotti, JE | 1 |
| Kessler, SM | 1 |
| Simon, Y | 1 |
| Gemperlein, K | 1 |
| Gianmoena, K | 1 |
| Cadenas, C | 1 |
| Zimmer, V | 1 |
| Pokorny, J | 1 |
| Barghash, A | 1 |
| Helms, V | 1 |
| van Rooijen, N | 1 |
| Bohle, RM | 1 |
| Lammert, F | 1 |
| Hengstler, JG | 1 |
| Mueller, R | 1 |
| Haybaeck, J | 1 |
| Kiemer, AK | 1 |
| Thapaliya, S | 1 |
| Inzaugarat, ME | 1 |
| Berk, M | 1 |
| Dixon, L | 1 |
| Papouchado, BG | 1 |
| Ishizu-Higashi, S | 1 |
| Seno, H | 1 |
| Nishi, E | 1 |
| Matsumoto, Y | 1 |
| Ikuta, K | 1 |
| Tsuda, M | 1 |
| Takada, Y | 1 |
| Nakanishi, Y | 1 |
| Kanda, K | 1 |
| Komekado, H | 1 |
| Chiba, T | 2 |
| Terashima, Y | 1 |
| Nishiumi, S | 1 |
| Minami, A | 1 |
| Kawano, Y | 1 |
| Hoshi, N | 1 |
| Azuma, T | 1 |
| Yoshida, M | 1 |
| Zhao, J | 1 |
| Peng, J | 1 |
| Hong, Z | 1 |
| She, W | 1 |
| Jiang, W | 1 |
| Tanaka, H | 1 |
| Fukahori, S | 1 |
| Baba, S | 1 |
| Ueno, T | 1 |
| Sivakumar, R | 1 |
| Yagi, M | 1 |
| Asagiri, K | 1 |
| Ishii, S | 1 |
| Tanaka, Y | 1 |
| Yu, D | 1 |
| Shu, XO | 1 |
| Xiang, YB | 1 |
| Gao, YT | 1 |
| Zheng, W | 1 |
| Song, H | 1 |
| Wang, L | 1 |
| Shu, X | 1 |
| Chong, LW | 1 |
| Hsu, YC | 1 |
| Lee, TF | 1 |
| Lin, Y | 1 |
| Chiu, YT | 1 |
| Yang, KC | 1 |
| Wu, JC | 1 |
| Huang, YT | 2 |
| Liu, Q | 1 |
| Yu, F | 1 |
| Yu, N | 1 |
| Shi, M | 1 |
| Dzierlenga, AL | 3 |
| Nelson, NR | 1 |
| Werts, S | 1 |
| Machado, MV | 2 |
| Michelotti, GA | 2 |
| Xie, G | 2 |
| Almeida Pereira, T | 1 |
| de Almeida, TP | 2 |
| Boursier, J | 2 |
| Bohnic, B | 2 |
| Guy, CD | 2 |
| Santos, JC | 1 |
| de Araújo, OR | 1 |
| Valentim, IB | 1 |
| de Andrade, KQ | 1 |
| Moura, FA | 1 |
| Smaniotto, S | 1 |
| dos Santos, JM | 1 |
| Gasparotto, J | 1 |
| Gelain, DP | 1 |
| Goulart, MO | 1 |
| Song, S | 1 |
| He, B | 1 |
| Gao, X | 1 |
| Chen, YM | 1 |
| Zhou, RF | 1 |
| Chen, XL | 1 |
| Tan, XY | 1 |
| Zheng, RD | 1 |
| Zhang, HW | 1 |
| Ling, WH | 1 |
| Zhu, HL | 1 |
| Sherriff, JL | 1 |
| O'Sullivan, TA | 1 |
| Properzi, C | 1 |
| Oddo, JL | 1 |
| Adams, LA | 1 |
| Yamamoto, H | 1 |
| Ikuta, T | 1 |
| Arihiro, K | 1 |
| Sugiyama, A | 1 |
| Kishikawa, N | 1 |
| Kim, SB | 2 |
| Kang, OH | 1 |
| Lee, YS | 1 |
| Ahn, YS | 1 |
| Cha, SW | 1 |
| Seo, YS | 1 |
| Kong, R | 1 |
| Kwon, DY | 2 |
| Cappelletti, M | 1 |
| Huppert, SS | 1 |
| Iwakura, Y | 1 |
| Dong, C | 1 |
| Shanmukhappa, SK | 1 |
| Li, YH | 1 |
| Choi, DH | 1 |
| Lee, EH | 1 |
| Seo, SR | 1 |
| Lee, S | 1 |
| Cho, EH | 1 |
| Strekalova, T | 1 |
| Costa-Nunes, JP | 1 |
| Veniaminova, E | 1 |
| Kubatiev, A | 1 |
| Lesch, KP | 1 |
| Chekhonin, VP | 1 |
| Evans, MC | 1 |
| Steinbusch, HW | 1 |
| Ma, C | 1 |
| Kesarwala, AH | 1 |
| Eggert, T | 1 |
| Medina-Echeverz, J | 1 |
| Kleiner, DE | 1 |
| Jin, P | 1 |
| Stroncek, DF | 1 |
| Terabe, M | 1 |
| Kapoor, V | 1 |
| ElGindi, M | 1 |
| Han, M | 1 |
| Thornton, AM | 1 |
| Egger, M | 1 |
| Felsher, DW | 1 |
| McVicar, DW | 1 |
| Weber, A | 1 |
| Heikenwalder, M | 1 |
| Greten, TF | 1 |
| Han, T | 1 |
| Fuscoe, JC | 1 |
| Ross, SA | 1 |
| Takeuchi-Yorimoto, A | 1 |
| Yamaura, Y | 1 |
| Kanki, M | 1 |
| Ide, T | 1 |
| Nakata, A | 1 |
| Noto, T | 1 |
| Cho, SJ | 1 |
| Cho, HJ | 1 |
| Chong, S | 1 |
| Chung, SJ | 1 |
| Kang, IM | 1 |
| Lee, JI | 1 |
| Yoon, IS | 1 |
| Kim, DD | 1 |
| Laho, T | 1 |
| Klein, DM | 1 |
| Micuda, S | 1 |
| Cao, Y | 1 |
| Chen, C | 1 |
| Qi, R | 1 |
| Suzuki, S | 1 |
| Sato, Y | 1 |
| Itoh, T | 1 |
| Umegaki, K | 1 |
| Ishioka, M | 1 |
| Miura, K | 1 |
| Minami, S | 1 |
| Shimura, Y | 1 |
| Ohnishi, H | 1 |
| Nishio, T | 1 |
| Taura, K | 1 |
| Iwaisako, K | 1 |
| Koyama, Y | 1 |
| Tanabe, K | 1 |
| Yamamoto, G | 1 |
| Okuda, Y | 1 |
| Ikeno, Y | 1 |
| Yoshino, K | 1 |
| Kasai, Y | 1 |
| Okuno, M | 1 |
| Seo, S | 1 |
| Sakurai, T | 1 |
| Asagiri, M | 1 |
| Hatano, E | 1 |
| Uemoto, S | 1 |
| Zimny, S | 1 |
| Neumann, M | 1 |
| Eisinger, K | 2 |
| Weiss, TS | 2 |
| Saleh, DO | 1 |
| Ahmed, RF | 1 |
| Amin, MM | 1 |
| Luo, F | 1 |
| Lingyun, M | 1 |
| Nakano, I | 1 |
| Ishikawa, T | 1 |
| Feng, GG | 1 |
| Katano, Y | 1 |
| Kohama, T | 1 |
| Kitaura, Y | 1 |
| Shimomura, Y | 1 |
| Mokhtari, Z | 1 |
| Gibson, DL | 1 |
| Hekmatdoost, A | 1 |
| Cordero, P | 1 |
| Campion, J | 1 |
| Rinella, ME | 1 |
| Siddiqui, MS | 1 |
| Gardikiotes, K | 1 |
| Gottstein, J | 1 |
| Elias, M | 1 |
| Green, RM | 1 |
| Ling, J | 1 |
| Chaba, T | 1 |
| Zhu, LF | 1 |
| Vance, DE | 1 |
| Wanninger, J | 1 |
| Bauer, S | 1 |
| Walter, R | 1 |
| Hellerbrand, C | 1 |
| Schäffler, A | 1 |
| Higuchi, A | 1 |
| Walsh, K | 1 |
| Corbin, KD | 1 |
| Zeisel, SH | 1 |
| Henao-Mejia, J | 1 |
| Elinav, E | 1 |
| Jin, C | 1 |
| Hao, L | 1 |
| Mehal, WZ | 1 |
| Strowig, T | 1 |
| Thaiss, CA | 1 |
| Kau, AL | 1 |
| Eisenbarth, SC | 1 |
| Jurczak, MJ | 1 |
| Camporez, JP | 1 |
| Shulman, GI | 1 |
| Gordon, JI | 1 |
| Flavell, RA | 1 |
| Guerrerio, AL | 1 |
| Colvin, RM | 1 |
| Schwartz, AK | 1 |
| Molleston, JP | 1 |
| Murray, KF | 1 |
| Diehl, A | 1 |
| Mohan, P | 1 |
| Schwimmer, JB | 1 |
| Torbenson, MS | 1 |
| Scheimann, AO | 1 |
| Yang, YY | 1 |
| Tsai, TH | 1 |
| Hou, MC | 1 |
| Lee, FY | 1 |
| Lee, SD | 1 |
| Lin, HC | 1 |
| Marcolin, E | 1 |
| San-Miguel, B | 1 |
| Vallejo, D | 1 |
| Tieppo, J | 1 |
| Marroni, N | 1 |
| González-Gallego, J | 1 |
| Tuñón, MJ | 1 |
| Mas, E | 1 |
| Danjoux, M | 1 |
| Garcia, V | 1 |
| Carpentier, S | 1 |
| Ségui, B | 1 |
| Levade, T | 1 |
| Tosello-Trampont, AC | 1 |
| Landes, SG | 1 |
| Nguyen, V | 1 |
| Novobrantseva, TI | 1 |
| Hahn, YS | 1 |
| Davaatseren, M | 1 |
| Hur, HJ | 1 |
| Yang, HJ | 1 |
| Hwang, JT | 1 |
| Park, JH | 1 |
| Kim, MS | 1 |
| Kim, MJ | 1 |
| Sung, MJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Statins for Prevention of Disease Progression and Hospitalization in Liver Cirrhosis: A Multi-center, Randomized, Double Blind, Placebo-controlled Trial. The STATLiver Trial[NCT04072601] | Phase 4 | 78 participants (Actual) | Interventional | 2019-11-08 | Terminated (stopped due to Study part one completed) | ||
| Effects of Choline Supplementation on Fetal Growth in Gestational Diabetes Mellitus[NCT04302168] | 60 participants (Anticipated) | Interventional | 2020-04-01 | Recruiting | |||
| The Impact Of Choline Administration On Oxidative Stress And Clinical Outcome Of Patients With Non-Alcoholic Fatty Liver Disease NAFLD[NCT05200156] | 100 participants (Anticipated) | Interventional | 2022-02-01 | Recruiting | |||
| The Role of Microbiome Reprogramming on Liver Fat Accumulation[NCT03914495] | 57 participants (Actual) | Interventional | 2019-05-21 | Terminated (stopped due to PI carefully considered multiple factors and decided to close study to any further enrollment.) | |||
| Role of Probiotics in Treatment of Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) Patients by Assessing With Fibroscan[NCT04671186] | 47 participants (Actual) | Interventional | 2020-09-07 | Completed | |||
| Investigation of Microbiome-based Prognostical Biomarkers in Patients With Morbid Obesity and Bariatric Surgery[NCT03391401] | 204 participants (Actual) | Observational | 2018-03-01 | Completed | |||
| Clinical Research Network in Nonalcoholic Steatohepatitis: Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC)[NCT00063635] | Phase 3 | 173 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| Clinical Research Network in Nonalcoholic Steatohepatitis: Pioglitazone vs. Vitamin E vs. Placebo for the Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (PIVENS)[NCT00063622] | Phase 3 | 247 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00063635)
Timeframe: baseline and 96 weeks
| Intervention | kg/m-squared (Mean) |
|---|---|
| Metformin | 1.3 |
| Vitamin E | 2.1 |
| Placebo | 1.9 |
Histological activity was assessed using the NAFLD activity score on a scale of 0 to 8, with higher scores indicating more severe disease; the components of this measure include steatosis (0-3), lobular inflammation (0-3), and hepatocellular ballooning (0-2). (NCT00063635)
Timeframe: baseline and 96 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Metformin | -1.1 |
| Vitamin E | -1.8 |
| Placebo | -0.7 |
Change in self-reported QOL physical health Pediatric Quality of Life Inventory (version 4.0) scores were recorded to range from 0 to 100 with increasing scores indicating better quality of life. (NCT00063635)
Timeframe: baseline and 96 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Metformin | 4.0 |
| Vitamin E | 6.0 |
| Placebo | 5.6 |
Change in self-reported QOL physical health Pediatric Quality of Life Inventory (version 4.0) scores were recorded to range from 0 to 100 with increasing scores indicating better quality of life. (NCT00063635)
Timeframe: baseline and 96 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Metformin | 5.4 |
| Vitamin E | 7.6 |
| Placebo | 5.4 |
(NCT00063635)
Timeframe: baseline and 96 weeks
| Intervention | IU/L (Mean) |
|---|---|
| Metformin | -21.5 |
| Vitamin E | -22.8 |
| Placebo | -20.4 |
Change in alpha-Tocopherol (NCT00063635)
Timeframe: baseline and 96 weeks
| Intervention | mg/L (Mean) |
|---|---|
| Metformin | -0.5 |
| Vitamin E | 9.4 |
| Placebo | -0.9 |
Ballooning is assessed on a scale of 0 to 2 with higher scores indicating more severe ballooning. This secondary outcome measure is the number of participants that experienced a decrease in ballooning score at 96 weeks compared to baseline, which indicates improvement in ballooning. (NCT00063635)
Timeframe: baseline and 96 weeks
| Intervention | participants (Number) |
|---|---|
| Metformin | 22 |
| Vitamin E | 22 |
| Placebo | 10 |
Fibrosis is assessed on a scale of 0 to 4 with higher scores indicating more severe fibrosis. This secondary outcome measure is the number of participants that experienced a decrease in fibrosis score at 96 weeks compared to baseline, which indicates improvement in fibrosis. (NCT00063635)
Timeframe: baseline and 96 weeks
| Intervention | participants (Number) |
|---|---|
| Metformin | 22 |
| Vitamin E | 18 |
| Placebo | 19 |
Lobular inflammation is assessed on a scale of 0 to 3 with higher scores indicating more severe lobular inflammation. This secondary outcome measure is the number of participants that experienced a decrease in lobular inflammation score at 96 weeks compared to baseline, which indicates improvement in lobular inflammation. (NCT00063635)
Timeframe: baseline and 96 weeks
| Intervention | participants (Number) |
|---|---|
| Metformin | 23 |
| Vitamin E | 22 |
| Placebo | 20 |
Steatosis is assessed on a scale of 0 to 3 with higher scores indicating more severe steatosis. This secondary outcome measure is the number of participants that experienced a decrease in steatosis score at 96 weeks compared to baseline, which indicates improvement in steatosis. (NCT00063635)
Timeframe: baseline and 96 weeks
| Intervention | participants (Number) |
|---|---|
| Metformin | 26 |
| Vitamin E | 27 |
| Placebo | 19 |
The primary outcome was sustained reduction in ALT level, defined as 50% or less of the baseline level or 40 IU/L or less at each visit from 48 to 96 weeks of treatment. (NCT00063635)
Timeframe: baseline and 96 weeks
| Intervention | participants (Number) |
|---|---|
| Metformin | 9 |
| Vitamin E | 15 |
| Placebo | 10 |
Fibrosis is assessed on a scale of 0 to 4 with higher scores indicating more severe fibrosis. This secondary outcome measure is the number of participants that experienced a decrease in fibrosis score, which indicates improvement in fibrosis. (NCT00063622)
Timeframe: baseline and 96 weeks
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 31 |
| Vitamin E | 33 |
| Placebo | 22 |
Hepatocellular ballooning is assessed on a scale of 0 to 2 with higher scores indicating more severe hepatocellular ballooning. This secondary outcome measure is the number of participants that experienced a decrease in hepatocellular ballooning score, which indicates improvement in hepatocellular ballooning. (NCT00063622)
Timeframe: baseline and 96 weeks
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 31 |
| Vitamin E | 40 |
| Placebo | 21 |
Lobular inflammation is assessed on a scale of 0 to 3 with higher scores indicating more severe lobular inflammation. This secondary outcome measure is the number of participants that experienced a decrease in lobular inflammation score, which indicates improvement in lobular inflammation. (NCT00063622)
Timeframe: baseline and 96 weeks
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 41 |
| Vitamin E | 43 |
| Placebo | 25 |
Total nonalcoholic fatty liver disease (NAFLD) activity was assessed on a scale of 0 to 8, with higher scores indicating more severe disease; the components of this measure include steatosis (assessed on a scale of 0 to 3), lobular inflammation (assessed on a scale of 0 to 3), and hepatocellular ballooning (assessed on a scale of 0 to 2). The primary outcome was an improvement in histological findings from baseline to 96 weeks, which required an improvement by 1 or more points in the hepatocellular ballooning score; no increase in the fibrosis score; and either a decrease in the activity score for nonalcoholic fatty liver disease to a score of 3 or less or a decrease in the activity score of at least 2 points, with at least a 1-point decrease in either the lobular inflammation or steatosis score. (NCT00063622)
Timeframe: baseline and 96 weeks
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 27 |
| Vitamin E | 36 |
| Placebo | 16 |
Steatosis is assessed on a scale of 0 to 3 with higher scores indicating more severe steatosis. This secondary outcome measure is the number of participants that experienced a decrease in steatosis score, which indicates improvement in steatosis. (NCT00063622)
Timeframe: baseline and 96 weeks
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 48 |
| Vitamin E | 43 |
| Placebo | 22 |
The criteria for nonalcoholic steatohepatitis was definite or possible steatohepatitis (assessed by a pathologist) with an activity score of 5 or more, or definite steatohepatitis (confirmed by two pathologists) with an activity score of 4. This secondary outcome measure is the number of participants who met this definition at baseline and did not meet this definition after 96 weeks of treatment and thus had a resolution of steatohepatitis. (NCT00063622)
Timeframe: baseline and 96 weeks
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 33 |
| Vitamin E | 29 |
| Placebo | 15 |
14 reviews available for choline and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Gut-liver axis-mediated mechanism of liver cancer: A special focus on the role of gut microbiota.
Topics: Bile Acids and Salts; Carcinoma, Hepatocellular; Cellular Senescence; Choline; DNA Damage; Ethanol; | 2021 |
A Comparison of the Gene Expression Profiles of Non-Alcoholic Fatty Liver Disease between Animal Models of a High-Fat Diet and Methionine-Choline-Deficient Diet.
Topics: Animals; Choline; Choline Deficiency; Diet, High-Fat; Disease Models, Animal; Hepatocytes; Humans; M | 2022 |
Stratifying Non-alcoholic Steatohepatitis With the Non-invasive Ultrasound Markers Shear Wave Dispersion Slope and Shear Wave Velocity: An Animal Study.
Topics: Animals; Biomarkers; Choline; Fibrosis; Liver; Liver Cirrhosis; Male; Methionine; Non-alcoholic Fatt | 2022 |
The contribution of the gut-liver axis to the immune signaling pathway of NAFLD.
Topics: Bile Acids and Salts; Choline; Ethanol; Humans; Non-alcoholic Fatty Liver Disease; Signal Transducti | 2022 |
The Role of Choline, Soy Isoflavones, and Probiotics as Adjuvant Treatments in the Prevention and Management of NAFLD in Postmenopausal Women.
Topics: Choline; Female; Humans; Isoflavones; Non-alcoholic Fatty Liver Disease; Postmenopause; Probiotics | 2023 |
One-Carbon Metabolism and Nonalcoholic Fatty Liver Disease: The Crosstalk between Nutrients, Microbiota, and Genetics.
Topics: Animals; Betaine; Carbon; Choline; Disease Progression; Female; Folic Acid; Gastrointestinal Microbi | 2020 |
The Relationship between Choline Bioavailability from Diet, Intestinal Microbiota Composition, and Its Modulation of Human Diseases.
Topics: Animals; Biological Availability; Cardiovascular Diseases; Choline; Diet; Dysbiosis; Gastrointestina | 2020 |
Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease Progression.
Topics: Animals; Choline; Disease Progression; Dysbiosis; Fecal Microbiota Transplantation; Gastrointestinal | 2020 |
Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis.
Topics: Animals; Bile Acids and Salts; Choline; Diet; Disease Progression; Dysbiosis; Endotoxemia; Energy In | 2018 |
Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota.
Topics: Animals; Bile Acids and Salts; Choline; Dietary Supplements; Energy Metabolism; Fecal Microbiota Tra | 2018 |
Choline-related-inherited metabolic diseases-A mini review.
Topics: Animals; Choline; Choline Deficiency; Dietary Supplements; Disease Progression; Humans; Liver; Metab | 2019 |
Choline, Its Potential Role in Nonalcoholic Fatty Liver Disease, and the Case for Human and Bacterial Genes.
Topics: Bacteria; Choline; Deficiency Diseases; Humans; Liver; Non-alcoholic Fatty Liver Disease; Phosphatid | 2016 |
Nonalcoholic Fatty Liver Disease, the Gut Microbiome, and Diet.
Topics: Choline; Diet; Fatty Acids, Omega-3; Gastrointestinal Microbiome; Humans; Intestines; Liver; Non-alc | 2017 |
Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression.
Topics: Animals; Choline; Disease Progression; Fatty Liver; Humans; Liver; Metabolic Syndrome; Non-alcoholic | 2012 |
Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression.
Topics: Animals; Choline; Disease Progression; Fatty Liver; Humans; Liver; Metabolic Syndrome; Non-alcoholic | 2012 |
Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression.
Topics: Animals; Choline; Disease Progression; Fatty Liver; Humans; Liver; Metabolic Syndrome; Non-alcoholic | 2012 |
Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression.
Topics: Animals; Choline; Disease Progression; Fatty Liver; Humans; Liver; Metabolic Syndrome; Non-alcoholic | 2012 |
3 trials available for choline and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Randomised trial of chronic supplementation with a nutraceutical mixture in subjects with non-alcoholic fatty liver disease.
Topics: Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Choline; Curcumin; Dieta | 2020 |
Efficacy of docosahexaenoic acid-choline-vitamin E in paediatric NASH: a randomized controlled clinical trial.
Topics: Adolescent; Biomarkers; Biopsy; Child; Child Nutritional Physiological Phenomena; Choline; Combined | 2017 |
Choline intake in a large cohort of patients with nonalcoholic fatty liver disease.
Topics: Adolescent; Adult; Aged; Aging; Biopsy; Child; Choline; Choline Deficiency; Cohort Studies; Cross-Se | 2012 |
Choline intake in a large cohort of patients with nonalcoholic fatty liver disease.
Topics: Adolescent; Adult; Aged; Aging; Biopsy; Child; Choline; Choline Deficiency; Cohort Studies; Cross-Se | 2012 |
Choline intake in a large cohort of patients with nonalcoholic fatty liver disease.
Topics: Adolescent; Adult; Aged; Aging; Biopsy; Child; Choline; Choline Deficiency; Cohort Studies; Cross-Se | 2012 |
Choline intake in a large cohort of patients with nonalcoholic fatty liver disease.
Topics: Adolescent; Adult; Aged; Aging; Biopsy; Child; Choline; Choline Deficiency; Cohort Studies; Cross-Se | 2012 |
184 other studies available for choline and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Trans-anethole attenuates diet-induced nonalcoholic steatohepatitis through suppressing TGF-β-mediated fibrosis.
Topics: Allylbenzene Derivatives; Animals; Anisoles; Choline; Diet; Liver; Liver Cirrhosis; Methionine; Mice | 2022 |
Hepatoprotective effects of gemigliptin and empagliflozin in a murine model of diet-induced non-alcoholic fatty liver disease.
Topics: Amino Acids; Animals; Benzhydryl Compounds; Choline; Cytokines; Diet, High-Fat; Disease Models, Anim | 2022 |
SU5, a new Auraptene analog with improved metabolic stability, ameliorates nonalcoholic fatty liver disease in methionine- and choline-deficient diet-fed db/db mice.
Topics: Animals; Choline; Coumarins; Diet; Disease Models, Animal; Down-Regulation; Half-Life; Humans; Lipid | 2022 |
Hepatic galectin-3 is associated with lipid droplet area in non-alcoholic steatohepatitis in a new swine model.
Topics: Animals; Choline; Diet, High-Fat; Dietary Carbohydrates; Dietary Fats; Disease Models, Animal; Galec | 2022 |
Water Specific MRI T1 Mapping for Evaluating Liver Inflammation Activity Grades in Rats With Methionine-Choline-Deficient Diet-Induced Nonalcoholic Fatty Liver Disease.
Topics: Animals; Area Under Curve; Biopsy; Choline; Diet; Inflammation; Liver; Magnetic Resonance Imaging; M | 2022 |
Ubiquitin-specific peptidase 10 ameliorates hepatic steatosis in nonalcoholic steatohepatitis model by restoring autophagic activity.
Topics: Animals; Autophagy; Choline; Fibrosis; Inflammation; Liver; Mice; Mice, Inbred C57BL; Non-alcoholic | 2022 |
Astaxanthin Attenuates Nonalcoholic Steatohepatitis with Downregulation of Osteoprotegerin in Ovariectomized Mice Fed Choline-Deficient High-Fat Diet.
Topics: Animals; Choline; Diet; Diet, High-Fat; Down-Regulation; Estrogens; Female; Fibrosis; Humans; Liver; | 2023 |
Melatonin Attenuates Inflammation, Oxidative Stress, and DNA Damage in Mice with Nonalcoholic Steatohepatitis Induced by a Methionine- and Choline-Deficient Diet.
Topics: Alanine Transaminase; Animals; Anti-Inflammatory Agents; Antioxidants; Aspartate Aminotransferases; | 2022 |
Chlorogenic acid alleviated liver fibrosis in methionine and choline deficient diet-induced nonalcoholic steatohepatitis in mice and its mechanism.
Topics: Animals; Chlorogenic Acid; Choline; Choline Deficiency; Diet; Endothelial Cells; HMGB1 Protein; Live | 2022 |
Rifaximin and lubiprostone mitigate liver fibrosis development by repairing gut barrier function in diet-induced rat steatohepatitis.
Topics: Acetamides; Amino Acids; Animals; Caco-2 Cells; Chloride Channels; Choline; Diet; Humans; Lipopolysa | 2022 |
AGK regulates the progression to NASH by affecting mitochondria complex I function.
Topics: Animals; Choline; Electron Transport Complex I; Liver; Methionine; Mice; Mice, Inbred C57BL; Mitocho | 2022 |
Indole supplementation ameliorates MCD-induced NASH in mice.
Topics: Animals; Choline; Choline Deficiency; Diet; Dietary Supplements; Disease Models, Animal; Indoles; In | 2022 |
The improvement of nonalcoholic steatohepatitis by Poria cocos polysaccharides associated with gut microbiota and NF-κB/CCL3/CCR1 axis.
Topics: Animals; Chemokine CCL3; Chemokines; Choline; Gastrointestinal Microbiome; Inflammation; Liver; Meth | 2022 |
Dynein light chain LC8 alleviates nonalcoholic steatohepatitis by inhibiting NF-κB signaling and reducing oxidative stress.
Topics: Animals; Choline; Cytoplasmic Dyneins; Diet; Disease Models, Animal; Dyneins; Inflammation; Liver; M | 2022 |
MCD Diet Rat Model Induces Alterations in Zinc and Iron during NAFLD Progression from Steatosis to Steatohepatitis.
Topics: Animals; Choline; Diet; Fatty Acids; Iron; Liver; Male; Methionine; Mice; Mice, Inbred C57BL; Non-al | 2022 |
Cell-specific Deletion of NLRP3 Inflammasome Identifies Myeloid Cells as Key Drivers of Liver Inflammation and Fibrosis in Murine Steatohepatitis.
Topics: Adenosine; Amino Acids; Animals; Caspases; Choline; Hepatitis; Humans; Inflammasomes; Inflammation; | 2022 |
Hydroxynonenal Causes Hepatocyte Death by Disrupting Lysosomal Integrity in Nonalcoholic Steatohepatitis.
Topics: Aldehyde Dehydrogenase; Animals; Cathepsins; Choline; Hepatocytes; Humans; Inflammation; Lipids; Lys | 2022 |
RNA helicase DEAD-box protein 5 alleviates nonalcoholic steatohepatitis progression via tethering TSC complex and suppressing mTORC1 signaling.
Topics: Animals; Carcinoma, Hepatocellular; Choline; DEAD-box RNA Helicases; Diet, High-Fat; Disease Models, | 2023 |
Lipidomic profiling of the hepatic esterified fatty acid composition in diet-induced nonalcoholic fatty liver disease in genetically diverse Collaborative Cross mice.
Topics: Animals; Choline; Collaborative Cross Mice; Diet, High-Fat; Disease Models, Animal; Fatty Acids; Fat | 2022 |
FOSL2 deficiency delays nonalcoholic steatohepatitis progression by regulating LY6D-mediated NLRP3 activation.
Topics: Animals; Antigens, Ly; Choline; GPI-Linked Proteins; Lipopolysaccharides; Liver; Methionine; Mice; N | 2022 |
Hepatocyte-Secreted Autotaxin Exacerbates Nonalcoholic Fatty Liver Disease Through Autocrine Inhibition of the PPARα/FGF21 Axis.
Topics: Animals; Antibodies, Neutralizing; Choline; Diet, High-Fat; Hepatocytes; Lysophosphatidylcholines; M | 2022 |
Depletion of hepatic stellate cells inhibits hepatic steatosis in mice.
Topics: Amino Acids; Animals; CD36 Antigens; Choline; Cytokines; Disease Models, Animal; Fatty Acids; Glioto | 2022 |
Differential progression of unhealthy diet-induced hepatocellular carcinoma in obese and non-obese mice.
Topics: Animals; Carcinoma, Hepatocellular; Cholesterol; Choline; Diet, High-Fat; Disease Models, Animal; Di | 2022 |
IL-23 signaling is not an important driver of liver inflammation and fibrosis in murine non-alcoholic steatohepatitis models.
Topics: Amino Acids; Animals; Carcinoma, Hepatocellular; Choline; Disease Models, Animal; Hepatitis; Inflamm | 2022 |
Alanyl-Glutamine Protects Mice against Methionine- and Choline-Deficient-Diet-Induced Steatohepatitis and Fibrosis by Modulating Oxidative Stress and Inflammation.
Topics: Alanine Transaminase; Animals; Anti-Inflammatory Agents; Antioxidants; Aspartate Aminotransferases; | 2022 |
Deleting Gata4 in hepatocytes promoted the progression of NAFLD via increasing steatosis and apoptosis, and desensitizing insulin signaling.
Topics: Animals; Apoptosis; Choline; Diet, High-Fat; GATA4 Transcription Factor; Hepatocytes; Insulin; Liver | 2023 |
Melatonin alleviates diet-induced steatohepatitis by targeting multiple cell types in the liver to suppress inflammation and fibrosis.
Topics: Animals; Choline; Diet; Disease Models, Animal; Humans; Inflammation; Lipids; Liver; Liver Cirrhosis | 2023 |
Marked gut microbiota dysbiosis and increased imidazole propionate are associated with a NASH Göttingen Minipig model.
Topics: Amino Acids; Animals; Choline; Dysbiosis; Gastrointestinal Microbiome; Male; Non-alcoholic Fatty Liv | 2022 |
Marked gut microbiota dysbiosis and increased imidazole propionate are associated with a NASH Göttingen Minipig model.
Topics: Amino Acids; Animals; Choline; Dysbiosis; Gastrointestinal Microbiome; Male; Non-alcoholic Fatty Liv | 2022 |
Marked gut microbiota dysbiosis and increased imidazole propionate are associated with a NASH Göttingen Minipig model.
Topics: Amino Acids; Animals; Choline; Dysbiosis; Gastrointestinal Microbiome; Male; Non-alcoholic Fatty Liv | 2022 |
Marked gut microbiota dysbiosis and increased imidazole propionate are associated with a NASH Göttingen Minipig model.
Topics: Amino Acids; Animals; Choline; Dysbiosis; Gastrointestinal Microbiome; Male; Non-alcoholic Fatty Liv | 2022 |
Differential methylation patterns in lean and obese non-alcoholic steatohepatitis-associated hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cholesterol; Choline; Fructose; Liver Neoplasms; Mice; Non-alcoh | 2022 |
Differential methylation patterns in lean and obese non-alcoholic steatohepatitis-associated hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cholesterol; Choline; Fructose; Liver Neoplasms; Mice; Non-alcoh | 2022 |
Differential methylation patterns in lean and obese non-alcoholic steatohepatitis-associated hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cholesterol; Choline; Fructose; Liver Neoplasms; Mice; Non-alcoh | 2022 |
Differential methylation patterns in lean and obese non-alcoholic steatohepatitis-associated hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cholesterol; Choline; Fructose; Liver Neoplasms; Mice; Non-alcoh | 2022 |
Dietary Choline Mitigates High-Fat Diet-Impaired Chylomicrons Assembly via UPRer Modulated by
Topics: Choline; Diet, High-Fat; DNA Methylation; Humans; Lipids; Non-alcoholic Fatty Liver Disease; Unfolde | 2022 |
Dietary Choline Mitigates High-Fat Diet-Impaired Chylomicrons Assembly via UPRer Modulated by
Topics: Choline; Diet, High-Fat; DNA Methylation; Humans; Lipids; Non-alcoholic Fatty Liver Disease; Unfolde | 2022 |
Dietary Choline Mitigates High-Fat Diet-Impaired Chylomicrons Assembly via UPRer Modulated by
Topics: Choline; Diet, High-Fat; DNA Methylation; Humans; Lipids; Non-alcoholic Fatty Liver Disease; Unfolde | 2022 |
Dietary Choline Mitigates High-Fat Diet-Impaired Chylomicrons Assembly via UPRer Modulated by
Topics: Choline; Diet, High-Fat; DNA Methylation; Humans; Lipids; Non-alcoholic Fatty Liver Disease; Unfolde | 2022 |
Diosgenin alleviates nonalcoholic steatohepatitis through affecting liver-gut circulation.
Topics: Animals; Choline; Disease Models, Animal; Intestines; Liver; Methionine; Mice; Mice, Inbred C57BL; N | 2023 |
Gut microbiota and bile acids partially mediate the improvement of fibroblast growth factor 21 on methionine-choline-deficient diet-induced non-alcoholic fatty liver disease mice.
Topics: Animals; Bile Acids and Salts; Choline; Diet; Dysbiosis; Gastrointestinal Microbiome; Liver; Methion | 2023 |
Low-Dose Administration of Cannabigerol Attenuates Inflammation and Fibrosis Associated with Methionine/Choline Deficient Diet-Induced NASH Model via Modulation of Cannabinoid Receptor.
Topics: Animals; Body Weight; Choline; Choline Deficiency; Diet; Fibrosis; Humans; Inflammation; Liver; Live | 2022 |
Extraction, characterization, and anti-nonalcoholic steatohepatitis activity of a (1,3) (1,6)-β-D-glucan from the Polyporus umbellatus (Pers.) Fries.
Topics: Animals; Choline; Diet; Glucans; Inflammation; Liver; Methionine; Mice; Mice, Inbred C57BL; Non-alco | 2023 |
Saroglitazar suppresses the hepatocellular carcinoma induced by intraperitoneal injection of diethylnitrosamine in C57BL/6 mice fed on choline deficient, l-amino acid- defined, high-fat diet.
Topics: Amino Acids; Animals; Carcinoma, Hepatocellular; Choline; Diet, High-Fat; Diethylnitrosamine; Diseas | 2023 |
(Pro)Renin Receptor Antagonism Attenuates High-Fat-Diet-Induced Hepatic Steatosis.
Topics: Animals; Choline; Diet, High-Fat; Fibrosis; Lipids; Liver; Methionine; Mice; Mice, Inbred C57BL; Non | 2023 |
Lower adiposity does not protect beta-2 syntrophin null mice from hepatic steatosis and inflammation in experimental non-alcoholic steatohepatitis.
Topics: Adiposity; Animals; Cholesterol Esters; Choline; Disease Models, Animal; Fatty Acid Synthases; Fatty | 2023 |
Fructooligosaccharides attenuate non-alcoholic fatty liver disease by remodeling gut microbiota and association with lipid metabolism.
Topics: Animals; Choline; Diet, High-Fat; Gastrointestinal Microbiome; Lipid Metabolism; Liver; Methionine; | 2023 |
Theabrownin ameliorates liver inflammation, oxidative stress, and fibrosis in MCD diet-fed C57BL/6J mice.
Topics: Animals; Choline; Choline Deficiency; Diabetes Mellitus, Type 2; Diet; Fibrosis; Inflammation; Methi | 2023 |
Qingrequzhuo capsule alleviated methionine and choline deficient diet-induced nonalcoholic steatohepatitis in mice through regulating gut microbiota, enhancing gut tight junction and inhibiting the activation of TLR4/NF-κB signaling pathway.
Topics: Animals; Choline; Diet; Drugs, Chinese Herbal; Endotoxemia; Gastrointestinal Microbiome; Inflammatio | 2022 |
Baicalein alleviates non-alcoholic fatty liver disease in mice by ameliorating intestinal barrier dysfunction.
Topics: Animals; Choline; Flavanones; Gastrointestinal Diseases; Intestinal Diseases; Liver; Methionine; Mic | 2023 |
Lingguizhugan decoction improves non-alcoholic steatohepatitis partially by modulating gut microbiota and correlated metabolites.
Topics: Animals; Choline; Chromatography, Liquid; Drugs, Chinese Herbal; Gastrointestinal Microbiome; Liver; | 2023 |
Osteoprotegerin deficiency aggravates methionine-choline-deficient diet-induced nonalcoholic steatohepatitis in mice.
Topics: Animals; Choline; Choline Deficiency; Diet; Dual-Specificity Phosphatases; Liver; Methionine; Mice; | 2023 |
Prenatal Choline Supplement in a Maternal Obesity Model Modulates Offspring Hepatic Lipidomes.
Topics: Animals; Choline; Diet, High-Fat; Dietary Supplements; Female; Humans; Lipidomics; Liver; Male; Mate | 2023 |
Thermoneutral housing shapes hepatic inflammation and damage in mouse models of non-alcoholic fatty liver disease.
Topics: Alanine Transaminase; Animals; Carbon Tetrachloride; Choline; Disease Models, Animal; Housing; Infla | 2023 |
Decreased Paneth cell α-defensins promote fibrosis in a choline-deficient L-amino acid-defined high-fat diet-induced mouse model of nonalcoholic steatohepatitis via disrupting intestinal microbiota.
Topics: alpha-Defensins; Amino Acids; Animals; Choline; Diet, High-Fat; Dysbiosis; Gastrointestinal Microbio | 2023 |
Chrysin and its nanoliposome ameliorated non-alcoholic steatohepatitis via inhibiting TLR4 signalling pathway.
Topics: Animals; Choline; Diet; Disease Models, Animal; Flavonoids; Liver; Methionine; Mice; Mice, Inbred C5 | 2023 |
Absence of Either Ripk3 or Mlkl Reduces Incidence of Hepatocellular Carcinoma Independent of Liver Fibrosis.
Topics: Animals; Carcinoma, Hepatocellular; Choline; Diet, High-Fat; Female; Incidence; Inflammation; Liver; | 2023 |
Simultaneous imaging of ultrasonic relative backscatter and attenuation coefficients for quantitative liver steatosis assessment.
Topics: Animals; Choline; Liver; Non-alcoholic Fatty Liver Disease; Rats; Ultrasonics; Ultrasonography | 2023 |
Qing-Zhi-Tiao-Gan-Tang (QZTGT) prevents nonalcoholic steatohepatitis (NASH) by expression pattern correction.
Topics: Animals; Choline; Diet; Disease Models, Animal; Liver; Liver Cirrhosis; Mice; Mice, Inbred C57BL; No | 2023 |
Pharmacology of a Potent and Novel Inhibitor of the NOD-Like Receptor Pyrin Domain-Containing Protein 3 (NLRP3) Inflammasome that Attenuates Development of Nonalcoholic Steatohepatitis and Liver Fibrosis.
Topics: Animals; Caspase 1; Choline; Inflammasomes; Inflammation; Interleukin-1beta; Liver Cirrhosis; Mice; | 2023 |
Faecal Microbiota transplantation affects liver DNA methylation in Non-alcoholic fatty liver disease: a multi-omics approach.
Topics: Choline; DNA Methylation; Fecal Microbiota Transplantation; Gastrointestinal Microbiome; Humans; Mul | 2023 |
MCD Diet Modulates HuR and Oxidative Stress-Related HuR Targets in Rats.
Topics: Animals; Choline; Diet; Disease Models, Animal; Liver; Male; Methionine; Mice; Mice, Inbred C57BL; N | 2023 |
Endothelial autophagy is not required for liver regeneration after partial hepatectomy in mice with fatty liver.
Topics: Animals; Autophagy; Choline; Diet, High-Fat; Disease Models, Animal; Endothelial Cells; Focal Nodula | 2023 |
iTRAQ-based quantitative proteomics analysis of the effect of ACT001 on non-alcoholic steatohepatitis in mice.
Topics: Animals; Choline; Disease Models, Animal; Inflammation; Isotope Labeling; Liver; Liver Cirrhosis; Me | 2023 |
Coral calcium carried hydrogen ameliorates the severity of non-alcoholic steatohepatitis induced by a choline deficient high carbohydrate fat-free diet in elderly rats.
Topics: Animals; Calcium; Carbohydrates; Choline; Diet, Fat-Restricted; Diet, High-Fat; Liver; Male; Non-alc | 2023 |
miR-21-5p promotes NASH-related hepatocarcinogenesis.
Topics: Animals; Carcinogenesis; Carcinoma, Hepatocellular; Choline; Liver; Liver Neoplasms; Mice; MicroRNAs | 2023 |
Nonalcoholic steatohepatitis-associated hepatocarcinogenesis in mice fed a modified choline-deficient, methionine-lowered, L-amino acid-defined diet and the role of signal changes.
Topics: Amino Acids; Animals; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Choline; Choline D | 2023 |
Icariin Supplementation Suppresses the Markers of Ferroptosis and Attenuates the Progression of Nonalcoholic Steatohepatitis in Mice Fed a Methionine Choline-Deficient Diet.
Topics: Animals; Choline; Choline Deficiency; Diet; Dietary Supplements; Ferroptosis; Flavonoids; Liver; Met | 2023 |
Dietary choline intake and non-alcoholic fatty liver disease (NAFLD) in U.S. adults: National Health and Nutrition Examination Survey (NHANES) 2017-2018.
Topics: Adult; Choline; Diet; Female; Humans; Logistic Models; Male; Non-alcoholic Fatty Liver Disease; Nutr | 2023 |
Gemigliptin, a DPP4 inhibitor, ameliorates nonalcoholic steatohepatitis through AMP-activated protein kinase-independent and ULK1-mediated autophagy.
Topics: AMP-Activated Protein Kinases; Animals; Autophagy; Autophagy-Related Protein-1 Homolog; Choline; Dia | 2023 |
CARD9 deficiency aggravated nonalcoholic steatohepatitis in mice through increasing inflammatory response.
Topics: Animals; Choline; Diet, High-Fat; Disease Models, Animal; Liver Cirrhosis; Methionine; Mice; Non-alc | 2024 |
Deletion of hepatic small heterodimer partner ameliorates development of nonalcoholic steatohepatitis in mice.
Topics: Animals; Cholesterol; Choline; Inflammation; Liver; Methionine; Mice; Mice, Inbred C57BL; Mice, Knoc | 2023 |
Comparison of effects of HucMSCs, exosomes, and conditioned medium on NASH.
Topics: AMP-Activated Protein Kinases; Animals; Choline; Collagen; Culture Media, Conditioned; Exosomes; Hum | 2023 |
Lactobacillus plantarum ameliorates NASH-related inflammation by upregulating L-arginine production.
Topics: Animals; Choline; Diet, High-Fat; Disease Models, Animal; Hepatitis; Humans; Inflammation; Lactobaci | 2023 |
Cerium oxide nanoparticles display antilipogenic effect in rats with non-alcoholic fatty liver disease.
Topics: Adipokines; Animals; Body Weight; Cerium; Cholesterol; Choline; Diet; Fatty Acids; Gene Expression R | 2019 |
Role and mechanisms of action of microRNA‑21 as regards the regulation of the WNT/β‑catenin signaling pathway in the pathogenesis of non‑alcoholic fatty liver disease.
Topics: Animals; Antagomirs; beta Catenin; Choline; Disease Models, Animal; Gene Expression Regulation; Glyc | 2019 |
Downregulation of GNAI3 Promotes the Pathogenesis of Methionine/Choline-Deficient Diet-Induced Nonalcoholic Fatty Liver Disease.
Topics: Animals; Choline; Disease Models, Animal; Down-Regulation; GTP-Binding Protein alpha Subunits, Gi-Go | 2020 |
Metabolic impact of partial hepatectomy in the non-alcoholic steatohepatitis animal model of methionine-choline deficient diet.
Topics: Animals; Choline; Diet; Disease Models, Animal; Hepatectomy; Lipid Metabolism; Liver; Liver Neoplasm | 2020 |
Multi-technique comparison of atherogenic and MCD NASH models highlights changes in sphingolipid metabolism.
Topics: Animals; Atherosclerosis; Choline; Diet; Diet, Atherogenic; Disease Models, Animal; Gene Expression | 2019 |
Dysregulated FXR-FGF19 signaling and choline metabolism are associated with gut dysbiosis and hyperplasia in a novel pig model of pediatric NASH.
Topics: Age Factors; Animals; Bile Acids and Salts; Choline; Colon; Disease Models, Animal; Dysbiosis; Femal | 2020 |
Targeting Hepatic Glutaminase 1 Ameliorates Non-alcoholic Steatohepatitis by Restoring Very-Low-Density Lipoprotein Triglyceride Assembly.
Topics: Adult; Animals; Choline; Disease Models, Animal; Female; Glutaminase; Hepatocytes; Humans; Lipid Met | 2020 |
Placental extract ameliorates liver fibrosis in a methionine- and choline-deficient diet-induced mouse model of non-alcoholic steatohepatitis.
Topics: Animal Feed; Animals; Body Weight; Choline; Diet; Disease Models, Animal; Female; Hepatic Stellate C | 2020 |
Targeting ferroptosis alleviates methionine-choline deficient (MCD)-diet induced NASH by suppressing liver lipotoxicity.
Topics: Animals; Choline; Choline Deficiency; Diet; Ferroptosis; Liver; Methionine; Mice; Mice, Inbred C57BL | 2020 |
Reduced Serum Cholesterol and Triglyceride Levels in a Choline-Deficient L-Amino Acid-Defined High-Fat Diet (CDAHFD)-Induced Mouse Model of Non-alcoholic Steatohepatitis (NASH).
Topics: Amino Acids; Animals; CD36 Antigens; Cholesterol; Choline; Choline Deficiency; Diet, High-Fat; Disea | 2020 |
Sweroside Prevents Non-Alcoholic Steatohepatitis by Suppressing Activation of the NLRP3 Inflammasome.
Topics: Animals; Caspase 1; Choline; Diet; Disease Models, Animal; DNA, Mitochondrial; Gene Expression Regul | 2020 |
The Effects of B1344, a Novel Fibroblast Growth Factor 21 Analog, on Nonalcoholic Steatohepatitis in Nonhuman Primates.
Topics: Animals; Body Weight; Cell Line; Choline; Fibroblast Growth Factors; Fibrosis; Inflammation; Liver; | 2020 |
Exogenous Liposomal Ceramide-C6 Ameliorates Lipidomic Profile, Energy Homeostasis, and Anti-Oxidant Systems in NASH.
Topics: Adenylate Kinase; Animals; Antioxidants; Apoptosis; Cell Proliferation; Ceramides; Choline; Diet; Di | 2020 |
Fucoxanthin inhibits hepatic oxidative stress, inflammation, and fibrosis in diet-induced nonalcoholic steatohepatitis model mice.
Topics: Alanine Transaminase; Amino Acids; Animals; Anti-Inflammatory Agents; Aspartate Aminotransferases; B | 2020 |
Arachidonate 12S-lipoxygenase of platelet-type in hepatic stellate cells of methionine and choline-deficient diet-fed mice.
Topics: Animals; Arachidonate 12-Lipoxygenase; Choline; Choline Deficiency; Diet; Disease Models, Animal; He | 2020 |
Citrus reticulata Blanco peel extract ameliorates hepatic steatosis, oxidative stress and inflammation in HF and MCD diet-induced NASH C57BL/6 J mice.
Topics: Animals; Choline; Citrus; Diet, High-Fat; Disease Models, Animal; Fruit; Humans; Liver; Male; Methio | 2020 |
Treatment of Non-Alcoholic Steatosis: Preclinical Study of a New Nutraceutical Multitarget Formulation.
Topics: alpha-Tocopherol; Animals; Anti-Inflammatory Agents; Antioxidants; Cells, Cultured; Chlorogenic Acid | 2020 |
MCD diet-induced steatohepatitis generates a diurnal rhythm of associated biomarkers and worsens liver injury in Klf10 deficient mice.
Topics: Animals; Apoptosis; Biomarkers; Caspase 3; Cells, Cultured; Choline; Circadian Rhythm; Diet; Disease | 2020 |
The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet.
Topics: Animals; Choline; Diet; Glucagon-Like Peptide-1 Receptor; Inflammation; Liraglutide; Liver; Methioni | 2021 |
Effect of Betaine Supplementation on Liver Tissue and Ultrastructural Changes in Methionine-Choline-Deficient Diet-Induced NAFLD.
Topics: Animals; Betaine; Choline; Collagen; Diet; Dietary Supplements; Disease Models, Animal; Hepatocytes; | 2020 |
Trimethylamine N-oxide levels are associated with NASH in obese subjects with type 2 diabetes.
Topics: Adult; Betaine; Bile Acids and Salts; Biomarkers; Biopsy; Choline; Diabetes Mellitus, Type 2; Female | 2021 |
Automated thermal imaging for the detection of fatty liver disease.
Topics: Algorithms; Animals; Automation; Choline; Choline Deficiency; Diet; Disease Models, Animal; Fatty Li | 2020 |
The endothelial dysfunction blocker CU06-1004 ameliorates choline-deficient L-amino acid diet-induced non-alcoholic steatohepatitis in mice.
Topics: Alanine Transaminase; Amino Acids; Animals; Cell Adhesion; Choline; Diet; Disease Models, Animal; En | 2020 |
Hepatic lipid profile in mice fed a choline-deficient, low-methionine diet resembles human non-alcoholic fatty liver disease.
Topics: alpha-Fetoproteins; Animal Feed; Animals; Carcinoma, Hepatocellular; Ceramides; Choline; Choline Def | 2020 |
A trans fatty acid substitute enhanced development of liver proliferative lesions induced in mice by feeding a choline-deficient, methionine-lowered, L-amino acid-defined, high-fat diet.
Topics: Amino Acids; Animal Feed; Animals; Apoptosis; Body Weight; Choline; Choline Deficiency; Diet, High-F | 2020 |
The pharmacodynamic and differential gene expression analysis of PPAR α/δ agonist GFT505 in CDAHFD-induced NASH model.
Topics: Amino Acids; Animals; Chalcones; Choline; Choline Deficiency; Diet, High-Fat; Disease Models, Animal | 2020 |
Inhibition of hyaluronan synthesis by 4-methylumbelliferone ameliorates non-alcoholic steatohepatitis in choline-deficient L-amino acid-defined diet-induced murine model.
Topics: Amino Acids; Animals; Choline; Choline Deficiency; Hyaluronic Acid; Hymecromone; Indicators and Reag | 2021 |
Therapeutic potential of puerarin against methionine-choline-deficient diet-induced non-alcoholic steatohepatitis determined by combination of
Topics: Animals; Choline; Diet; Disease Models, Animal; Genes, rRNA; Isoflavones; Liver; Magnetic Resonance | 2021 |
SIRT1/NFκB pathway mediates anti-inflammatory and anti-apoptotic effects of rosmarinic acid on in a mouse model of nonalcoholic steatohepatitis (NASH).
Topics: Animals; Anti-Inflammatory Agents; Choline; Cinnamates; Depsides; Disease Models, Animal; Liver; Met | 2022 |
BMP9 promotes methionine- and choline-deficient diet-induced nonalcoholic steatohepatitis in non-obese mice by enhancing NF-κB dependent macrophage polarization.
Topics: Adenoviridae; Animals; Cell Differentiation; Choline; Cytokines; Diet; Disease Models, Animal; Gene | 2021 |
Caspase-11-Mediated Hepatocytic Pyroptosis Promotes the Progression of Nonalcoholic Steatohepatitis.
Topics: Animals; Caspases, Initiator; Choline; Diet; Disease Progression; Hepatocytes; Inflammation; Lipopol | 2021 |
Silybin alleviates hepatic lipid accumulation in methionine-choline deficient diet-induced nonalcoholic fatty liver disease in mice via peroxisome proliferator-activated receptor α.
Topics: Animals; Choline; Diet; Lipid Metabolism; Liver; Methionine; Mice; Non-alcoholic Fatty Liver Disease | 2021 |
The PKM2 activator TEPP-46 attenuates MCD feeding-induced nonalcoholic steatohepatitis by inhibiting the activation of Kupffer cells.
Topics: Animals; Choline; Cytokines; Diet; Inflammasomes; Kupffer Cells; Liver; Male; Methionine; Mice, Inbr | 2021 |
Methionine- and Choline-Deficient Diet-Induced Nonalcoholic Steatohepatitis Is Associated with Increased Intestinal Inflammation.
Topics: Animals; Cell Line, Tumor; Choline; Diet; Epithelial Cells; Feeding Behavior; Humans; Inflammation; | 2021 |
[Parathyroid hormone-related protein aggravates nonalcoholic fatty liver disease induced by methionine choline-deficient diet in mice].
Topics: Animals; Choline; Diet; Disease Models, Animal; Liver; Male; Methionine; Mice; Mice, Inbred C57BL; N | 2021 |
Nonobese mice with nonalcoholic steatohepatitis fed on a choline-deficient, l-amino acid-defined, high-fat diet exhibit alterations in signaling pathways.
Topics: Amino Acids; Animals; Choline; Choline Deficiency; Diet, High-Fat; Disease Models, Animal; Lipid Met | 2021 |
Enhanced offspring predisposition to steatohepatitis with maternal high-fat diet is associated with epigenetic and microbiome alterations.
Topics: Animals; Choline; Choline Deficiency; Diet, High-Fat; Disease Models, Animal; DNA Methylation; Epige | 2017 |
Time-course microarrays reveal early activation of the immune transcriptome in a choline-deficient mouse model of liver injury.
Topics: Animals; Choline; Choline Deficiency; Chromatography, Liquid; Disease Models, Animal; Gene Expressio | 2017 |
Hepatocellular carcinoma in a mouse model fed a choline-deficient, L-amino acid-defined, high-fat diet.
Topics: Animals; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Choline; Choline Deficiency; Di | 2017 |
Perfluorooctane Sulfonate-Induced Hepatic Steatosis in Male Sprague Dawley Rats Is Not Attenuated by Dietary Choline Supplementation.
Topics: Alkanesulfonic Acids; Animals; Biomarkers; Cholesterol; Choline; Dietary Supplements; Environmental | 2017 |
Non-alcoholic steatohepatitis induces transient changes within the liver macrophage pool.
Topics: Animals; Antigens, Ly; Biomarkers; Cell Differentiation; Cell Proliferation; Choline; Female; Ki-67 | 2017 |
Dual role of protein tyrosine phosphatase 1B in the progression and reversion of non-alcoholic steatohepatitis.
Topics: Animals; Cells, Cultured; Choline; Diet; Epithelial Cell Adhesion Molecule; Fibroblast Growth Factor | 2018 |
Fatty acids in non-alcoholic steatohepatitis: Focus on pentadecanoic acid.
Topics: Animals; Choline; Choline Deficiency; Disease Models, Animal; Fatty Acids; Hepatocytes; Humans; Live | 2017 |
Butein protects the nonalcoholic fatty liver through mitochondrial reactive oxygen species attenuation in rats.
Topics: Administration, Oral; Albumins; Animals; Chalcones; Choline; Choline Deficiency; Diet; Globulins; He | 2018 |
Alisol A 24-acetate ameliorates nonalcoholic steatohepatitis by inhibiting oxidative stress and stimulating autophagy through the AMPK/mTOR pathway.
Topics: Adenylate Kinase; Animals; Autophagy; Cell Line; Cholestenones; Choline; Diet; Disease Models, Anima | 2018 |
HIF-1-dependent lipin1 induction prevents excessive lipid accumulation in choline-deficient diet-induced fatty liver.
Topics: Animals; Cells, Cultured; Choline; Diet; Hepatocytes; Hypoxia; Hypoxia-Inducible Factor 1, alpha Sub | 2018 |
Effect of Phyllanthus emblica L. fruit on methionine and choline-deficiency diet-induced nonalcoholic steatohepatitis.
Topics: Animals; Choline; Diet; Fruit; Humans; Interleukin-1beta; Lipid Peroxidation; Liver; Male; Methionin | 2018 |
Lycium barbarum polysaccharides improve hepatic injury through NFkappa-B and NLRP3/6 pathways in a methionine choline deficient diet steatohepatitis mouse model.
Topics: Animals; Antioxidants; Apoptosis; Choline; Diet; Disease Models, Animal; Drugs, Chinese Herbal; Fema | 2018 |
De novo NAD
Topics: Animals; Caenorhabditis elegans; Carboxy-Lyases; Cell Line; Choline; Conserved Sequence; Disease Mod | 2018 |
Triticum aestivum ethanolic extract improves non-alcoholic fatty liver disease in mice fed a choline-deficient or high-fat diet.
Topics: Animals; Choline; Diet, High-Fat; Humans; Lipid Metabolism; Liver; Male; Mice; Mice, Inbred C57BL; N | 2019 |
Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis.
Topics: Animals; Choline; Diet; Female; Hepatic Stellate Cells; Hepatocytes; Humans; Liver Cirrhosis; Male; | 2018 |
Macrophage Raptor Deficiency-Induced Lysosome Dysfunction Exacerbates Nonalcoholic Steatohepatitis.
Topics: Animals; Apoptosis; Calcium; Cholesterol; Choline; Diet; Disease Progression; Dynamins; Feeding Beha | 2019 |
Intestinal Microbiota Protects against MCD Diet-Induced Steatohepatitis.
Topics: Animals; Choline; Choline Deficiency; Diet, High-Fat; Disease Models, Animal; Gastrointestinal Micro | 2019 |
Evaluating the therapeutic potential of one-carbon donors in nonalcoholic fatty liver disease.
Topics: Animals; Betaine; Carbon; Choline; Diet, High-Fat; Dietary Supplements; DNA Methylation; Folic Acid; | 2019 |
Nutritional and lipidomics biomarkers of docosahexaenoic acid-based multivitamin therapy in pediatric NASH.
Topics: Adolescent; alpha-Linolenic Acid; Arachidonic Acid; Biomarkers; Child; Choline; Docosahexaenoic Acid | 2019 |
Antifibrotic Effects of 1,25(OH)
Topics: Actins; Alanine Transaminase; Animals; Aspartate Aminotransferases; Calcitriol; Choline; Collagen Ty | 2019 |
Nonalcoholic fatty liver disease alters microcystin-LR toxicokinetics and acute toxicity.
Topics: Animals; Cell Adhesion Molecules; Cholesterol; Choline; Diet, High-Fat; Hepatobiliary Elimination; I | 2019 |
Metabolic characterization of two different non-alcoholic fatty liver disease pre-clinical mouse models.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Body Weight; Cholesterol; Choline; Diet, | 2019 |
Epoxyeicosatrienoic acids alleviate methionine-choline-deficient diet-induced non-alcoholic steatohepatitis in mice.
Topics: Animals; Cell Line; Cell Line, Tumor; Chemokines; Choline; Cytochrome P-450 CYP2J2; Cytochrome P-450 | 2019 |
Sinapine reduces non-alcoholic fatty liver disease in mice by modulating the composition of the gut microbiota.
Topics: Animals; Bacteria; Brassica napus; Choline; Diet, High-Fat; Gastrointestinal Microbiome; Humans; Mal | 2019 |
Hepatoprotective Effect of Jianpi Huoxue Formula on Nonalcoholic Fatty Liver Disease Induced by Methionine-Choline-Deficient Diet in Rat.
Topics: Animals; Choline; Drugs, Chinese Herbal; Food, Formulated; Liver; Male; Methionine; Non-alcoholic Fa | 2019 |
Strain-dependent dysregulation of one-carbon metabolism in male mice is associated with choline- and folate-deficient diet-induced liver injury.
Topics: Animals; Carbon; Choline; Choline Deficiency; Cystathionine beta-Synthase; Disease Models, Animal; D | 2013 |
Oral choline tolerance test as a novel noninvasive method for predicting nonalcoholic steatohepatitis.
Topics: Administration, Oral; Adult; Aged; Area Under Curve; Case-Control Studies; Choline; Fasting; Fatty L | 2014 |
Nrf2 activators attenuate the progression of nonalcoholic steatohepatitis-related fibrosis in a dietary rat model.
Topics: Amino Acids; Animals; Anti-Inflammatory Agents; Antioxidants; Binding Sites; Cell Line; Choline; Die | 2013 |
Validated liquid chromatography-tandem mass spectrometry method for determination of totally nine probe metabolites of cytochrome P450 enzymes and UDP-glucuronosyltransferases.
Topics: Animals; Choline; Chromatography, Liquid; Cytochrome P-450 Enzyme System; Diet; Enzyme Assays; Fatty | 2013 |
Propranolol, a β-adrenoceptor antagonist, worsens liver injury in a model of non-alcoholic steatohepatitis.
Topics: Adrenergic beta-Antagonists; Alanine Transaminase; Animals; Apoptosis; Choline; Culture Media; Disea | 2013 |
Aldose reductase is involved in the development of murine diet-induced nonalcoholic steatohepatitis.
Topics: Aldehyde Reductase; Animals; Blotting, Western; Choline; Diet; Fatty Liver; Female; Interleukin-6; M | 2013 |
The effects of α-lipoic acid on liver oxidative stress and free fatty acid composition in methionine-choline deficient diet-induced NAFLD.
Topics: Animals; Choline; Diet; Fatty Acids, Nonesterified; Fatty Liver; Humans; Lipid Peroxidation; Liver; | 2014 |
Choline supplementation protects against liver damage by normalizing cholesterol metabolism in Pemt/Ldlr knockout mice fed a high-fat diet.
Topics: Animals; Cholesterol; Cholesterol Esters; Choline; Diet, High-Fat; Fatty Liver; Lipid Metabolism; Li | 2014 |
Prevention of nonalcoholic steatohepatitis in rats by two manganese-salen complexes.
Topics: Animals; Antioxidants; Ascorbic Acid; Chelating Agents; Choline; Diet; Ethylenediamines; Fatty Liver | 2014 |
Time-dependent changes and association between liver free fatty acids, serum lipid profile and histological features in mice model of nonalcoholic fatty liver disease.
Topics: Animals; Choline; Diet; Disease Models, Animal; Fatty Acids, Nonesterified; Fatty Liver; Hepatocytes | 2014 |
Role of adipose tissue in methionine-choline-deficient model of non-alcoholic steatohepatitis (NASH).
Topics: Adipogenesis; Adipose Tissue; Animals; Choline; Disease Models, Animal; Fatty Acids; Fatty Acids, No | 2014 |
Synergistic interaction between genetics and disease on pravastatin disposition.
Topics: Animals; Biological Transport, Active; Choline; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibito | 2014 |
GH administration rescues fatty liver regeneration impairment by restoring GH/EGFR pathway deficiency.
Topics: Animals; Blotting, Western; Cell Proliferation; Choline; Diet; Down-Regulation; ErbB Receptors; Fatt | 2014 |
Fatty acid elongation in non-alcoholic steatohepatitis and hepatocellular carcinoma.
Topics: Acetyltransferases; Animals; Carcinoma, Hepatocellular; Choline; Diet; Diethylnitrosamine; Disease M | 2014 |
Caspase 3 inactivation protects against hepatic cell death and ameliorates fibrogenesis in a diet-induced NASH model.
Topics: Animals; Antigens, Ly; Apoptosis; Caspase 3; Choline; Collagen; Dose-Response Relationship, Drug; Fa | 2014 |
Deletion of nardilysin prevents the development of steatohepatitis and liver fibrotic changes.
Topics: Amino Acids; Animals; Choline; Diet, High-Fat; Disease Resistance; Female; Gene Deletion; Liver Cirr | 2014 |
Metabolomics-based search for therapeutic agents for non-alcoholic steatohepatitis.
Topics: Animals; Choline; Diet; Fatty Liver; Liver; Liver Cirrhosis; Male; Metabolome; Methionine; Mice, Inb | 2014 |
Protective effects and mechanisms of total alkaloids of Rubus alceaefolius Poir on non‑alcoholic fatty liver disease in rats.
Topics: Adiponectin; Administration, Oral; Alanine Transaminase; Alkaloids; Animals; Aspartate Aminotransfer | 2014 |
3, 3'-Diindolylmethane alleviates steatosis and the progression of NASH partly through shifting the imbalance of Treg/Th17 cells to Treg dominance.
Topics: Animals; CD4-Positive T-Lymphocytes; Cells, Cultured; Choline; Diet; Female; Indoles; Liver; Methion | 2014 |
Branched-Chain Amino Acid-Rich Supplements Containing Microelements Have Antioxidant Effects on Nonalcoholic Steatohepatitis in Mice.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aldehydes; Amino Acids, Branched-Chain; Animals; Antioxidants; Choline; | 2016 |
Higher dietary choline intake is associated with lower risk of nonalcoholic fatty liver in normal-weight Chinese women.
Topics: Adult; Aged; Animals; Asian People; Body Mass Index; Body Weight; Choline; Choline Deficiency; Dose- | 2014 |
Hepatoprotective and antioxidant activities of extracts from Salvia-Nelumbinis naturalis against nonalcoholic steatohepatitis induced by methionine- and choline-deficient diet in mice.
Topics: Animal Feed; Animals; Antioxidants; Base Sequence; Choline; DNA Primers; Liver; Male; Methionine; Mi | 2014 |
Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells.
Topics: Actins; Animals; Choline; Collagen Type I; Culture Media, Conditioned; Diet; Fatty Acids, Monounsatu | 2015 |
[Emodin worsens methionine-choline-deficient diet-induced non-alcoholic fatty liver disease in mice].
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Body Weight; Choline; Diet; Emodin; Live | 2015 |
Mechanism of Altered Metformin Distribution in Nonalcoholic Steatohepatitis.
Topics: Animals; Choline; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Kidney; Liver; Metformin; Methioni | 2015 |
Mouse models of diet-induced nonalcoholic steatohepatitis reproduce the heterogeneity of the human disease.
Topics: Animals; Apoptosis; Choline; Choline Deficiency; Diet; Disease Models, Animal; Humans; Liver; Liver | 2015 |
Correction: Mouse Models of Diet-Induced Nonalcoholic Steatohepatitis Reproduce the Heterogeneity of the Human Disease.
Topics: Animals; Apoptosis; Choline; Choline Deficiency; Diet; Disease Models, Animal; Humans; Liver; Liver | 2015 |
Choline and Cystine Deficient Diets in Animal Models with Hepatocellular Injury: Evaluation of Oxidative Stress and Expression of RAGE, TNF-α, and IL-1β.
Topics: Animals; Body Weight; Catalase; Choline; Cystine; Diet; Disease Models, Animal; Interleukin-1beta; L | 2015 |
Protective role of autophagy in methionine-choline deficient diet-induced advanced nonalcoholic steatohepatitis in mice.
Topics: Animals; Autophagy; Choline; Diet; Endoplasmic Reticulum Stress; Fibrosis; Liver; Methionine; Mice; | 2016 |
Associations of gut-flora-dependent metabolite trimethylamine-N-oxide, betaine and choline with non-alcoholic fatty liver disease in adults.
Topics: Adolescent; Adult; Aged; Betaine; Biomarkers; Case-Control Studies; Choline; Chromatography, High Pr | 2016 |
Enhancing hepatic fibrosis in spontaneously hypertensive rats fed a choline-deficient diet: a follow-up report on long-term effects of oxidative stress in non-alcoholic fatty liver disease.
Topics: Animals; Choline; Diet; Disease Models, Animal; Follow-Up Studies; Lipotropic Agents; Liver; Male; N | 2016 |
Hepatoprotective Effect and Synergism of Bisdemethoycurcumin against MCD Diet-Induced Nonalcoholic Fatty Liver Disease in Mice.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Body Weight; Cholesterol; Choline; Choli | 2016 |
Regulation of Inflammation by IL-17A and IL-17F Modulates Non-Alcoholic Fatty Liver Disease Pathogenesis.
Topics: Animals; Choline; Diet; Disease Models, Animal; Hepatitis; Interleukin-17; Macrophages; Male; Methio | 2016 |
Sirtuin 3 (SIRT3) Regulates α-Smooth Muscle Actin (α-SMA) Production through the Succinate Dehydrogenase-G Protein-coupled Receptor 91 (GPR91) Pathway in Hepatic Stellate Cells.
Topics: Actins; Animals; Blotting, Western; Cells, Cultured; Choline; Choline Deficiency; Diet; Disease Mode | 2016 |
Insulin receptor sensitizer, dicholine succinate, prevents both Toll-like receptor 4 (TLR4) upregulation and affective changes induced by a high-cholesterol diet in mice.
Topics: Animals; Anxiety; Cholesterol; Choline; Depression; Diet; Female; Inflammation; Mice; Mice, Inbred C | 2016 |
NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis.
Topics: Animals; Carcinogenesis; Carcinoma, Hepatocellular; Case-Control Studies; CD4-Positive T-Lymphocytes | 2016 |
Status of hepatic DNA methylome predetermines and modulates the severity of non-alcoholic fatty liver injury in mice.
Topics: Animals; Choline; CpG Islands; Cytosine; Diet; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine- | 2016 |
MicroRNA-21 is associated with fibrosis in a rat model of nonalcoholic steatohepatitis and serves as a plasma biomarker for fibrotic liver disease.
Topics: Animals; Biomarkers; Choline; Choline Deficiency; Diet; Dietary Supplements; Disease Models, Animal; | 2016 |
Effects of Nonalcoholic Fatty Liver Disease on Hepatic CYP2B1 and in Vivo Bupropion Disposition in Rats Fed a High-Fat or Methionine/Choline-Deficient Diet.
Topics: Animals; Bupropion; Choline; Choline Deficiency; Cytochrome P-450 CYP2B1; Diet, High-Fat; Disease Mo | 2016 |
Effect of nonalcoholic steatohepatitis on renal filtration and secretion of adefovir.
Topics: Adenine; Animals; Choline; Diet; Glomerular Filtration Rate; Kidney; Male; Methionine; Non-alcoholic | 2016 |
Fenofibrate nanoliposome: Preparation and its inhibitory effects on nonalcoholic fatty liver disease in mice.
Topics: Animals; Choline; Fenofibrate; Hypolipidemic Agents; Liposomes; Liver; Methionine; Mice; Nanoparticl | 2016 |
Nonalcoholic Steatohepatitis Modulates Membrane Protein Retrieval and Insertion Processes.
Topics: Animals; Cell Membrane; Choline; Cytoskeletal Proteins; Intracellular Signaling Peptides and Protein | 2016 |
Evaluation of Methionine Content in a High-Fat and Choline-Deficient Diet on Body Weight Gain and the Development of Non-Alcoholic Steatohepatitis in Mice.
Topics: Animals; Biomarkers; Choline; Diet, High-Fat; Fibrosis; Gene Expression; Glucose Tolerance Test; Lip | 2016 |
Altered Gut Microbiota Composition and Immune Response in Experimental Steatohepatitis Mouse Models.
Topics: Alanine Transaminase; Animals; Bacteroidetes; Cholesterol; Choline; Clostridiales; Diet; Diet, High- | 2017 |
Hepatic vagus nerve regulates Kupffer cell activation via α7 nicotinic acetylcholine receptor in nonalcoholic steatohepatitis.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Chemokine CCL2; Chimera; Choline; Choline Deficien | 2017 |
Tubulin alpha 8 is expressed in hepatic stellate cells and is induced in transformed hepatocytes.
Topics: Aged; Aged, 80 and over; Animals; Cell Line, Tumor; Cell Transformation, Neoplastic; Choline; Diet, | 2017 |
Modulatory role of Co-enzyme Q10 on methionine and choline deficient diet-induced non-alcoholic steatohepatitis (NASH) in albino rats.
Topics: Alanine Transaminase; Alkaline Phosphatase; Ammonia; Animals; Aspartate Aminotransferases; Bilirubin | 2017 |
Branched-chain amino acids alleviate hepatic steatosis and liver injury in choline-deficient high-fat diet induced NASH mice.
Topics: Adipose Tissue; Amino Acids, Branched-Chain; Animals; Cholesterol; Choline; Citrate (si)-Synthase; D | 2017 |
Dietary supplementation with methyl donor groups could prevent nonalcoholic fatty liver.
Topics: Animals; Betaine; Choline; Dietary Fats; Dietary Sucrose; Dietary Supplements; Disease Models, Anima | 2011 |
Dysregulation of the unfolded protein response in db/db mice with diet-induced steatohepatitis.
Topics: Activating Transcription Factor 6; Animal Feed; Animals; Choline; Choline Deficiency; Cytokines; Dia | 2011 |
Hepatic ratio of phosphatidylcholine to phosphatidylethanolamine predicts survival after partial hepatectomy in mice.
Topics: Animals; Choline; Choline-Phosphate Cytidylyltransferase; Dietary Fats; Dietary Supplements; Disease | 2012 |
Adiponectin upregulates hepatocyte CMKLR1 which is reduced in human fatty liver.
Topics: Adiponectin; Aged; Animals; Bile Ducts; Choline; Diet; Fatty Liver; Female; Hepatic Stellate Cells; | 2012 |
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity.
Topics: Animals; Apoptosis Regulatory Proteins; CARD Signaling Adaptor Proteins; Carrier Proteins; Choline; | 2012 |
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity.
Topics: Animals; Apoptosis Regulatory Proteins; CARD Signaling Adaptor Proteins; Carrier Proteins; Choline; | 2012 |
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity.
Topics: Animals; Apoptosis Regulatory Proteins; CARD Signaling Adaptor Proteins; Carrier Proteins; Choline; | 2012 |
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity.
Topics: Animals; Apoptosis Regulatory Proteins; CARD Signaling Adaptor Proteins; Carrier Proteins; Choline; | 2012 |
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity.
Topics: Animals; Apoptosis Regulatory Proteins; CARD Signaling Adaptor Proteins; Carrier Proteins; Choline; | 2012 |
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity.
Topics: Animals; Apoptosis Regulatory Proteins; CARD Signaling Adaptor Proteins; Carrier Proteins; Choline; | 2012 |
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity.
Topics: Animals; Apoptosis Regulatory Proteins; CARD Signaling Adaptor Proteins; Carrier Proteins; Choline; | 2012 |
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity.
Topics: Animals; Apoptosis Regulatory Proteins; CARD Signaling Adaptor Proteins; Carrier Proteins; Choline; | 2012 |
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity.
Topics: Animals; Apoptosis Regulatory Proteins; CARD Signaling Adaptor Proteins; Carrier Proteins; Choline; | 2012 |
Kupffer cell depletion attenuates leptin-mediated methoxamine-stimulated portal perfusion pressure and thromboxane A2 release in a rodent model of NASH-cirrhosis.
Topics: Analysis of Variance; Animals; Arachidonic Acid; Benzofurans; Choline; Clodronic Acid; Diet, High-Fa | 2012 |
Quercetin treatment ameliorates inflammation and fibrosis in mice with nonalcoholic steatohepatitis.
Topics: Animals; Biomarkers; Choline; Choline Deficiency; Collagen Type I; Collagen Type III; Cyclooxygenase | 2012 |
The pro-inflammatory action of tumour necrosis factor-α in non-alcoholic steatohepatitis is independent of the NSMAF gene product.
Topics: Animals; Choline; Choline Deficiency; Diet; Disease Models, Animal; Fatty Liver; Intracellular Signa | 2013 |
Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factor-α production.
Topics: Animals; Chemokine CCL2; Chemokine CXCL10; Choline; Diet; Disease Models, Animal; Fatty Liver; Femal | 2012 |
Dandelion leaf extract protects against liver injury induced by methionine- and choline-deficient diet in mice.
Topics: Animals; Choline; Choline Deficiency; Fatty Liver; Humans; Interleukin-6; Liver; Male; Methionine; M | 2013 |